School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Christopher Flowers MD, MS

  • Department of Hematology and Medical Oncology
    Adjunct Professor
  • (404) 778-3942
  • crflowe@emory.edu
Head shot of Christopher Flowers

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
  • Adjunct Assistant Professor, Georgia Institute of Technology School of Industrial and Systems Engineering

Education

Degrees

  • MS from University of Washington
  • MS from Standford University
  • MD from Standford Univeristy School of Medicine
  • BA from Standford University

Research

Focus

  • As director of Emory's Lymphoma Program, I seek to develop a program aimed at attaining international leadership and risk-adapted, individualized patient care. My clinical research interests are in the areas of population sciences, translational research, and clinical trails and evidence- based treatment and care for patients with lymphoid malignancies.

Publications

  • Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
    Leuk Lymphoma Volume: 66 Page(s): 956 - 960
    05/01/2025 Authors: Gaulin C; Jain P; Nair R; Iyer SP; Lee HJ; Fayad L; Feng L; Ok CY; Kanagal-Shamanna R; Oriabure O
  • Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.
    Blood Adv
    04/08/2025 Authors: Saha S; Rehman L; Rehman A; Darbaniyan F; Weber DM; Becnel M; Gaballa MR; Thomas SK; Lee HC; Chang C-C
  • Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.
    Blood Adv Volume: 9 Page(s): 1485 - 1491
    04/08/2025 Authors: Chihara D; Steiner RE; Nair R; Feng L; Ahmed S; Strati P; Malpica L; Griffith DP; Mathew SA; Montinez W
  • Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.
    JAMA Netw Open Volume: 8 Page(s): e253455
    04/01/2025 Authors: Long JP; Prakash R; Edelkamp P; Knafl M; Lionel AC; Nair R; Ahmed S; Strati P; Castillo LEM; Al-Zaki A
  • Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 25 Page(s): e183 - e199.e8
    04/01/2025 Authors: Nastoupil LJ; Andersen CR; Ayers A; Wang Y; Habermann TM; Chihara D; Kahl BS; Link BK; Koff JL; Cohen JB
  • Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
    Am J Hematol Volume: 100 Page(s): 606 - 615
    04/01/2025 Authors: Yamshon S; Koff JL; Larson MC; Kahl BS; Casulo C; Lossos IS; Haddadi S; Stanchina M; Chihara D; Ayers A
  • Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
    Blood
    03/16/2025 Authors: Yang H; Zhang W; Ravanmehr V; Cui G; Bowman K; Chen R; Henderson J; Lockman SR; Rojas E; Wilson AL
  • Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.
    Blood Adv
    03/15/2025 Authors: Trnn M; Fogliato LM; Gardner F; Flinn IW; Larouche J-F; Haioun C; Canales MA; Goto H; Hajek R; Salles GA
  • Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.
    Blood Adv Volume: 9 Page(s): 1013 - 1023
    03/11/2025 Authors: Day JR; Larson MC; Durani U; Koff JL; Wang Y; Habermann TM; Lossos IS; Nastoupil LJ; Strouse C; Chihara D
  • Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.
    Blood Cancer Discov Volume: 6 Page(s): 79 - 93
    03/04/2025 Authors: Flowers CR; Anantha RW; Leautaud V; Desai P; Donald CE; Hildebrandt MAT; Koff JL; Tamimi RM; Cozen W; Nze C
  • End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
    Blood
    02/28/2025 Authors: Di M; Maurer MJ; Flowers CR
  • Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
    Blood Volume: 145 Page(s): 823 - 839
    02/20/2025 Authors: Prasad R; Rehman A; Rehman L; Darbaniyan F; Blumenberg V; Schubert M-L; Mor U; Zamir E; Schmidt S; Hayase T
  • New Approvals Advancing Blood Cancer Medicine.
    Blood Cancer Discov Volume: 6 Page(s): 5 - 9
    01/08/2025 Authors: AACR Cancer Progress Report 2024 Steering Committee
  • Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.
    Front Immunol Volume: 16 Page(s): 1517348
    01/01/2025 Authors: Manzar GS; Pinnix CC; Dudzinski SO; Marqueen KE; Cha EE; Nasr LF; Yoder AK; Rooney MK; Strati P; Ahmed S
  • Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.
    Front Immunol Volume: 16 Page(s): 1449693
    01/01/2025 Authors: Lyu M-A; Tang X; Raso MG; Huang M; Zeng K; Sadeghi T; Flowers CR; Parmar S
  • American Society of Hematology: building a comprehensive minority recruitment and retention professional program.
    Blood Adv Volume: 8 Page(s): 6237 - 6247
    12/24/2024 Authors: Rollins MR; Warsame RM; Smith M; Molina A; Rouce RH; Avalos BR; Johnson CS; Lopez JA; Thompson AA; Fanning L
  • Cancer in 2024.
    Cancer Discov Volume: 14 Page(s): 2324 - 2331
    12/02/2024 Authors: AACR Cancer Disparities Progress Report 2024 Steering Committee; AACR Cancer Progress Report 2024 Steering Committee
  • Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
    Adv Radiat Oncol Volume: 9 Page(s): 101650
    12/01/2024 Authors: Fang P; Noticewala SS; Wu SY; Gunther JR; Ludmir EB; Medeiros LJ; Strati P; Nair R; Nze C; Nastoupil LJ
  • Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
    Blood Volume: 144 Page(s): 2063 - 2066
    11/07/2024 Authors: Abro B; Maurer MJ; Habermann TM; Burack WR; Chapman JR; Cohen JB; Friedberg JW; Inghirami G; Kahl BS; Larson MC
  • Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
    Curr Med Res Opin Volume: 40 Page(s): 1863 - 1871
    11/01/2024 Authors: Trotman J; Zinzani PL; Song Y; Delarue R; Kim P; Ivanova E; Korde R; Mayer J; De Oliveira AC; Assouline SE
  • Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
    Nat Commun Volume: 15 Page(s): 8668
    10/07/2024 Authors: Zhang S; Jiang VC; Han G; Hao D; Lian J; Liu Y; Cai Q; Zhang R; McIntosh J; Wang R
  • CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation.
    iScience Volume: 27 Page(s): 110830
    09/20/2024 Authors: Huang M; Ke Z; Lyu M-A; Masarova L; Sadeghi T; Flowers CR; Parmar S
  • Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.
    Transplant Cell Ther Volume: 30 Page(s): 832 - 843
    09/01/2024 Authors: Iqbal M; Kumar A; Dreger P; Chavez J; Sauter CS; Sureda AM; Bachanova V; Maziarz RT; Dreyling M; Smith SM
  • Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol Volume: 10 Page(s): 1195 - 1203
    09/01/2024 Authors: Pinnix CC; Dabaja BS; Gunther JR; Fang PQ; Wu SY; Nastoupil LJ; Strati P; Nair R; Ahmed S; Steiner R
  • Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
    Blood Adv Volume: 8 Page(s): 4414 - 4422
    08/27/2024 Authors: Khurana A; Mwangi R; Nastoupil LJ; Reagan PM; Farooq U; Romancik JT; McDonnell TJ; Riska SM; Lossos LS; Kahl BS
  • Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase1/2trial.
    EClinicalMedicine Volume: 74 Page(s): 102747
    08/01/2024 Authors: Gurumurthi A; Chin CK; Feng L; Fowler NH; Strati P; Hagemeister FB; Fayad LE; Westin JR; Obi C; Arafat J
  • Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL.
    Blood Adv Volume: 8 Page(s): 3825 - 3837
    07/23/2024 Authors: Nze C; Andersen CR; Ayers AA; Westin J; Wang M; Iyer S; Ahmed S; Pinnix C; Vega F; Nguyen L
  • Defining primary refractory large B-cell lymphoma.
    Blood Adv Volume: 8 Page(s): 3402 - 3415
    07/09/2024 Authors: Bock AM; Mwangi R; Wang Y; Khurana A; Maurer MJ; Ayers A; Kahl BS; Martin P; Cohen JB; Casulo C
  • Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival.
    JNCI Cancer Spectr Volume: 8
    07/01/2024 Authors: Rodriguez ER; Tonn T; Jafry M; Ahmed S; Cuglievan B; Livingston JA; Flowers CR; Aune GJ; Albritton KH; Roth ME
  • Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Haematologica Volume: 109 Page(s): 2177 - 2185
    07/01/2024 Authors: Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
  • Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.
    Lancet Haematol Volume: 11 Page(s): e521 - e529
    07/01/2024 Authors: Gunther JR; Xu J; Bhutani MS; Strati P; Fang PQ; Wu SY; Dabaja BS; Dong W; Bhosale PR; Flowers CR
  • Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study.
    Am J Hematol Volume: 99 Page(s): 1230 - 1239
    07/01/2024 Authors: Ma S; La J; Swinnerton KN; Guffey D; Bandyo R; De Las Pozas G; Hanzelka K; Xiao X; Rojas-Hernandez CM; Amos CI
  • Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Am J Hematol Volume: 99 Page(s): 1281 - 1289
    07/01/2024 Authors: Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S
  • MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES.
    Ann Appl Stat Volume: 18 Page(s): 1360 - 1377
    06/01/2024 Authors: Chi S; Flowers CR; Li Z; Huang X; Wei P
  • Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
    CPT Pharmacometrics Syst Pharmacol Volume: 13 Page(s): 1055 - 1066
    06/01/2024 Authors: Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C
  • Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Blood Adv Volume: 8 Page(s): 2478 - 2490
    05/28/2024 Authors: Moslehi JJ; Furman RR; Tam CS; Salem J-E; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H
  • CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data.
    Sci Rep Volume: 14 Page(s): 10633
    05/09/2024 Authors: Wang Y; Flowers CR; Wang M; Huang X; Li Z
  • Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
    Haematologica Volume: 109 Page(s): 1460 - 1468
    05/01/2024 Authors: Jallouk AP; Kui N; Sun R; Westin JR; Steiner RE; Nair R; Nastoupil LJ; Fayad LE; Zaki AA; Hawkins M
  • Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Leuk Lymphoma Volume: 65 Page(s): 669 - 673
    05/01/2024 Authors: Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Haematologica Volume: 109 Page(s): 1194 - 1205
    04/01/2024 Authors: Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnn M
  • Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer Volume: 130 Page(s): 876 - 885
    03/15/2024 Authors: Gordon MJ; Feng L; Strati P; Lee HJ; Hagemeister FB; Westin JR; Samaniego F; Marques-Piubelli ML; Vega Vazquez F; Parra Cuentas ER
  • MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES.
    bioRxiv
    03/07/2024 Authors: Chi S; Flowers CR; Li Z; Huang X; Wei P
  • Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
    Nat Med Volume: 30 Page(s): 772 - 784
    03/01/2024 Authors: Marin D; Li Y; Basar R; Rafei H; Daher M; Dou J; Mohanty V; Dede M; Nieto Y; Uprety N
  • The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
    Am J Hematol Volume: 99 Page(s): 408 - 421
    03/01/2024 Authors: Cerhan JR; Maurer MJ; Link BK; Feldman AL; Habermann TM; Jaye DL; Burack WR; McDonnell TJ; Vega F; Chapman JR
  • The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.
    Exp Hematol Oncol Volume: 13 Page(s): 14
    02/07/2024 Authors: Yan F; Jiang V; Jordan A; Che Y; Liu Y; Cai Q; Xue Y; Li Y; McIntosh J; Chen Z
  • Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.
    Diagn Pathol Volume: 19 Page(s): 17
    01/19/2024 Authors: Tavolara TE; Niazi MKK; Feldman AL; Jaye DL; Flowers C; Cooper LAD; Gurcan MN
  • Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes.
    Front Transplant Volume: 3 Page(s): 1448650
    01/01/2024 Authors: Zeng K; Ma H; Huang M; Lyu M-A; Sadeghi T; Flowers CR; Parmar S
  • Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
    Br J Haematol Volume: 204 Page(s): e11 - e16
    01/01/2024 Authors: Mamlouk O; Strati P; Feng L; Sun R; Ayers A; Steiner RE; Nair R; Flowers C; Ramdial JL; Saini N
  • Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study.
    JCO Oncol Pract Volume: 20 Page(s): 137 - 144
    01/01/2024 Authors: Singh AP; Xiao L; O'Brien BJ; Blondeau CE; Flowers CR; Bruera E; Morris VK; Shah AY
  • The impact of a multidisciplinary goals-of-care program on unplanned readmission rates at a comprehensive cancer center.
    Support Care Cancer Volume: 32 Page(s): 66
    12/27/2023 Authors: Leung C; Andersen CR; Wilson K; Nortje N; George M; Flowers C; Bruera E; Hui D
  • Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
    J Hematol Oncol Volume: 16 Page(s): 122
    12/16/2023 Authors: Vose JM; Fu K; Wang L; Mansoor A; Stewart D; Cheng H; Smith L; Yuan J; Qureishi HN; Link BK
  • Barriers to accessing cellular therapy for patients receiving care in community practices.
    Hematology Am Soc Hematol Educ Program Volume: 2023 Page(s): 382 - 385
    12/08/2023 Authors: Nze C; Flowers CR
  • ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
    J Clin Oncol Volume: 41 Page(s): 5107 - 5117
    11/20/2023 Authors: Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P
  • A single-cell atlas of CD19 chimeric antigen receptor Tcells.
    Cancer Cell Volume: 41 Page(s): 1835 - 1837
    11/13/2023 Authors: Li X; Henderson J; Gordon MJ; Sheikh I; Nastoupil LJ; Westin J; Flowers C; Ahmed S; Wang L; Neelapu SS
  • Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma.
    Blood Cancer J Volume: 13 Page(s): 156
    10/12/2023 Authors: Jain P; Nomie K; Kotlov N; Segodin V; Hill H; Ok CY; Fetooh A; Kanagal-Shamanna R; Vega F; Bagaev A
  • Prolonged cytopenia following CD19 CAR Tcell therapy is linked with bone marrow infiltration of clonally expanded IFN-expressing CD8 Tcells.
    Cell Rep Med Volume: 4 Page(s): 101158
    08/15/2023 Authors: Strati P; Li X; Deng Q; Marques-Piubelli ML; Henderson J; Watson G; Deaton L; Cain T; Yang H; Ravanmehr V
  • Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
    Am J Hematol Volume: 98 Page(s): 1214 - 1222
    08/01/2023 Authors: Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K
  • Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells.
    Cells Volume: 12
    07/18/2023 Authors: Zeng K; Huang M; Lyu M-A; Khoury JD; Ahmed S; Patel KK; Dropuli B; Reese-Koc J; Caimi PF; Sadeghi T
  • Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS.
    Blood Adv Volume: 7 Page(s): 3075 - 3079
    07/11/2023 Authors: Gladstone DE; D'Alessio F; Howard C; Lyu M-A; Mock JR; Gibbs KW; Abrams D; Huang M; Zeng K; Herlihy JP
  • Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives.
    Br J Haematol Volume: 202 Page(s): 219 - 229
    07/01/2023 Authors: Chihara D; Nastoupil LJ; Flowers CR
  • External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center.
    Am J Hematol Volume: 98 Page(s): 1052 - 1057
    07/01/2023 Authors: Li A; De Las Pozas G; Andersen CR; Nze CC; Toale KM; Milner EM; Fillmore NR; Chiao EY; Rojas Hernandez C; Kroll MH
  • Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
    Blood Adv Volume: 7 Page(s): 2287 - 2296
    06/13/2023 Authors: Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M
  • 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
    Hematol Oncol Volume: 41 Suppl 2 Page(s): 167 - 168
    06/01/2023 Authors: Steiner RE; Strati P; Flowers CR; Neelapu SS; Green M; Nastoupil LJ; Hagemeister FB; Feng L; Ahmed S; Nair R
  • 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
    Hematol Oncol Volume: 41 Suppl 2 Page(s): 430 - 432
    06/01/2023 Authors: Bock AM; Mwangi R; Wang Y; Khurana A; Maurer MJ; Ayers A; Kahl B; Martin P; Cohen J; Casulo C
  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
    J Clin Oncol Volume: 41 Page(s): 3063 - 3071
    06/01/2023 Authors: Key NS; Khorana AA; Kuderer NM; Bohlke K; Lee AYY; Arcelus JI; Wong SL; Balaban EP; Flowers CR; Gates LE
  • Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.
    J Clin Oncol Volume: 41 Page(s): 2926 - 2938
    06/01/2023 Authors: Li A; La J; May SB; Guffey D; da Costa WL; Amos CI; Bandyo R; Milner EM; Kurian KM; Chen DCR
  • Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
    Blood Volume: 141 Page(s): 1888 - 1893
    04/13/2023 Authors: Alderuccio JP; Reis IM; Koff JL; Larson MC; Chihara D; Zhao W; Haddadi S; Habermann TM; Martin P; Chapman JR
  • A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
    Blood Adv Volume: 7 Page(s): 1137 - 1145
    04/11/2023 Authors: Cherng H-JJ; Alig SK; Oki Y; Nastoupil LJ; Fayad L; Neelapu SS; Turturro F; Hagemeister F; Craig AFM; Macaulay CW
  • Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
    Haematologica Volume: 108 Page(s): 1163 - 1167
    04/01/2023 Authors: Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N
  • A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
    Nat Med Volume: 29 Page(s): 906 - 916
    04/01/2023 Authors: Stein-Thoeringer CK; Saini NY; Zamir E; Blumenberg V; Schubert M-L; Mor U; Fante MA; Schmidt S; Hayase E; Hayase T
  • PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.
    Exp Hematol Oncol Volume: 12 Page(s): 32
    03/20/2023 Authors: Steiner RE; Parra ER; Vega F; Feng L; Westin JR; Neelapu SS; Strati P; Green MR; Flowers CR; Solis LM
  • Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
    Am J Hematol Volume: 98 Page(s): 449 - 463
    03/01/2023 Authors: Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER
  • Allogeneic cord blood regulatory T cells can resolve lung inflammation.
    Cytotherapy Volume: 25 Page(s): 245 - 253
    03/01/2023 Authors: Lyu M-A; Huang M; Zeng K; Li L; Khoury JD; Nishimoto M; Ma H; Sadeghi T; Mukherjee S; Slutsky AS
  • Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies.
    Cancers (Basel) Volume: 15
    02/28/2023 Authors: Hui D; Ahmed S; Nortje N; George M; Andersen CR; Wilson K; Urbauer D; Flowers C; Bruera E
  • Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    J Clin Oncol Volume: 41 Page(s): 745 - 755
    02/01/2023 Authors: Westin J; Davis RE; Feng L; Hagemeister F; Steiner R; Lee HJ; Fayad L; Nastoupil L; Ahmed S; Rodriguez A
  • Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    J Clin Invest Volume: 133
    02/01/2023 Authors: Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y
  • Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis.
    J Clin Oncol Volume: 41 Page(s): 579 - 589
    01/20/2023 Authors: Hui D; Nortje N; George M; Wilson K; Urbauer DL; Lenz CA; Wallace SK; Andersen CR; Mendoza T; Haque S
  • Immune-based therapies in diffuse large B-cell lymphoma.
    Expert Opin Investig Drugs Volume: 32 Page(s): 479 - 493
    01/01/2023 Authors: McCurry D; Flowers CR; Bermack C
  • Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia.
    Leuk Lymphoma Volume: 64 Page(s): 151 - 160
    01/01/2023 Authors: Lipscomb J; Switchenko JM; Flowers CR; Gillespie TW; Wortley PM; Bayakly AR; Almon L; Ward KC
  • Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
    Front Immunol Volume: 14 Page(s): 1217121
    01/01/2023 Authors: Lyu M-A; Tang X; Khoury JD; Raso MG; Huang M; Zeng K; Nishimoto M; Ma H; Sadeghi T; Flowers CR
  • Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
    Br J Haematol Volume: 200 Page(s): 35 - 44
    01/01/2023 Authors: Cherng H-JJ; Xu G; Feng L; Steiner R; Fayad L; Strati P; Nair R; Nastoupil LJ; Lee HJ; Neelapu SS
  • Sequencing therapy in relapsed DLBCL.
    Hematology Am Soc Hematol Educ Program Volume: 2022 Page(s): 146 - 154
    12/09/2022 Authors: Flowers CR; Odejide OO
  • BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS.
    Ann Appl Stat Volume: 16 Page(s): 2481 - 2504
    12/01/2022 Authors: Lin R; Shi H; Yin G; Thall PF; Yuan Y; Flowers CR
  • Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
    Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e1084 - e1091
    12/01/2022 Authors: Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
  • A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
    Cell Rep Med Volume: 3 Page(s): 100720
    11/15/2022 Authors: Fahrmann JF; Saini NY; Chia-Chi C; Irajizad E; Strati P; Nair R; Fayad LE; Ahmed S; Lee HJ; Iyer S
  • Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
    Leukemia Volume: 36 Page(s): 2669 - 2677
    11/01/2022 Authors: Strati P; Jallouk AP; Sun R; Choi J; Das K; Cherng H-J; Ahmed S; Lee HJ; Iyer SP; Nair R
  • Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
    Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e1009 - e1018
    11/01/2022 Authors: Dixon JG; alayan ; Chihara D; Nielsen T; Dimier N; Zheng J; Wall AK; Salles G; Morschhauser F; Marcus R
  • ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S358 - S359
    10/01/2022 Authors: Flowers C; Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trnn M; Sharman JP; Herbaux C; Burke JM; Matasar M
  • ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S355 - S356
    10/01/2022 Authors: Flowers CR; Burke JM; Vukcevic M; Snodgrass S; Saverno K; Lumiqued MAA; Abdulhaq H; Brem E; Evens A; Farooq U
  • The Impact of Sequence of Therapy for Older Patients With Follicular Lymphoma: SEER-Medicare Analysis.
    Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e938 - e946
    10/01/2022 Authors: Xie C; Li R; Huang X; Chihara D; Flowers CR
  • TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
    Mol Cancer Volume: 21 Page(s): 185
    09/26/2022 Authors: Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W
  • Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia.
    J Clin Invest Volume: 132
    09/15/2022 Authors: Chang A; Sholukh AM; Wieland A; Jaye DL; Carrington M; Huang M-L; Xie H; Jerome KR; Roychoudhury P; Greninger AL
  • Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
    Blood Cancer Discov Volume: 3 Page(s): 428 - 443
    09/06/2022 Authors: Han G; Deng Q; Marques-Piubelli ML; Dai E; Dang M; Ma MCJ; Li X; Yang H; Henderson J; Kudryashova O
  • Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
    Blood Cancer Discov Volume: 3 Page(s): 385 - 393
    09/06/2022 Authors: Saini NY; Swoboda DM; Greenbaum U; Ma J; Patel RD; Devashish K; Das K; Tanner MR; Strati P; Nair R
  • CondiS web app: imputation of censored lifetimes for machine learning-based survival analysis.
    Bioinformatics Volume: 38 Page(s): 4252 - 4254
    09/02/2022 Authors: Wang Y; Flowers CR; Li Z; Huang X
  • Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
    Lancet Volume: 400 Page(s): 512 - 521
    08/13/2022 Authors: Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP
  • Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
    Blood Adv Volume: 6 Page(s): 4413 - 4423
    08/09/2022 Authors: Luan D; Fatola T; Toure A; Flowers CR; Link B; Friedberg JW; Cohen JB; Kahl B; Lossos IS; Nastoupil L
  • Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
    Blood Volume: 140 Page(s): 504 - 515
    08/04/2022 Authors: Cherng H-JJ; Sun R; Sugg B; Irwin R; Yang H; Le CC; Deng Q; Fayad L; Fowler NH; Parmar S
  • Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations.
    Am J Hematol Volume: 97 Page(s): 1044 - 1054
    08/01/2022 Authors: da Costa WL; Guffey D; Oluyomi A; Bandyo R; Rosales O; Wallace CD; Granada C; Riaz N; Fitzgerald M; Garcia DA
  • SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.
    Cancer Discov Volume: 12 Page(s): 1782 - 1803
    07/06/2022 Authors: Leung W; Teater M; Durmaz C; Meydan C; Chivu AG; Chadburn A; Rice EJ; Muley A; Camarillo JM; Arivalagan J
  • CondiS: A conditional survival distribution-based method for censored data imputation overcoming the hurdle in machine learning-based survival analysis.
    J Biomed Inform Volume: 131 Page(s): 104117
    07/01/2022 Authors: Wang Y; Flowers CR; Li Z; Huang X
  • SIRP+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.
    Blood Adv Volume: 6 Page(s): 3286 - 3293
    06/14/2022 Authors: Marques-Piubelli ML; Parra ER; Feng L; Soto LS; Gallardo M; Gouni S; Samaniego F; Noorani M; Hagemeister FB; Westin JR
  • Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
    J Clin Oncol Volume: 40 Page(s): 1949 - 1957
    06/10/2022 Authors: Chihara D; Huang EP; Finnigan SR; Cordes LM; Skorupan N; Fukuda Y; Rubinstein LV; Ivy SP; Doroshow JH; Nastoupil LJ
  • Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.
    Blood Adv Volume: 6 Page(s): 2867 - 2871
    05/10/2022 Authors: Al Zaki A; Feng L; Watson G; Ahmed SA; Mistry H; Nastoupil LJ; Hawkins M; Nair R; Iyer SP; Lee HJ
  • Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
    Blood Adv Volume: 6 Page(s): 2745 - 2756
    05/10/2022 Authors: Harkins RA; Patel SP; Lee MJ; Switchenko JM; Ansell SM; Bartlett NL; Blum KA; Cashen AF; Casulo C; Friedberg JW
  • B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS.
    Cancer Epidemiol Biomarkers Prev Volume: 31 Page(s): 1103 - 1110
    05/04/2022 Authors: Wang SS; Vajdic CM; Linet MS; Slager SL; Voutsinas J; Nieters A; Casabonne D; Cerhan JR; Cozen W; Alarcn G
  • Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement.
    Blood Adv Volume: 6 Page(s): 2267 - 2274
    04/12/2022 Authors: Akin S; Hosing C; Khouri I; Ahmed S; Alousi A; Fowler N; Joseph J; Truxillo J; Ramdial JL; Maadani F
  • In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.
    JCI Insight Volume: 7
    04/08/2022 Authors: Li L; Muftuoglu M; Liang S; Basyal M; Lv J; Akdogan ME; Chen K; Andreeff M; Flowers CR; Parmar S
  • Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
    Leuk Lymphoma Volume: 63 Page(s): 821 - 833
    04/01/2022 Authors: Halwani AS; Panizo C; Isufi I; Herrera AF; Okada CY; Cull EH; Kis B; Chaves JM; Bartlett NL; Ai W
  • Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
    Lancet Haematol Volume: 9 Page(s): e289 - e300
    04/01/2022 Authors: Casulo C; Larson MC; Lunde JJ; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
  • Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood Volume: 139 Page(s): 1684 - 1693
    03/17/2022 Authors: Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C
  • Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    Lancet Oncol Volume: 23 Page(s): 406 - 415
    03/01/2022 Authors: Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y
  • PI3K/ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Blood Volume: 139 Page(s): 523 - 537
    01/27/2022 Authors: Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A
  • Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    N Engl J Med Volume: 386 Page(s): 351 - 363
    01/27/2022 Authors: Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trnn M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
    Blood Adv Volume: 6 Page(s): 533 - 543
    01/25/2022 Authors: Sehn LH; Hertzberg M; Opat S; Herrera AF; Assouline S; Flowers CR; Kim TM; McMillan A; Ozcan M; Safar V
  • Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    J Clin Oncol Volume: 40 Page(s): 202 - 212
    01/10/2022 Authors: Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y
  • A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma Volume: 63 Page(s): 74 - 83
    01/01/2022 Authors: Cherng H-JJ; Chuang HH; Steiner R; Fayad L; Strati P; Nair R; Hagemeister F; Nastoupil LJ; Lee HJ; Neelapu SS
  • Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
    Blood Adv Volume: 5 Page(s): 5179 - 5189
    12/14/2021 Authors: Bond DA; Switchenko JM; Villa D; Maddocks K; Churnetski M; Gerrie AS; Goyal S; Shanmugasundaram K; Calzada O; Kolla B
  • Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
    Am J Hematol Volume: 96 Page(s): 1374 - 1384
    11/01/2021 Authors: Karmali R; Switchenko JM; Goyal S; Shanmugasundaram K; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
  • Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma Volume: 62 Page(s): 2671 - 2678
    11/01/2021 Authors: Chihara D; Larson MC; Robinson DP; Thompson CA; Maurer MJ; Casulo C; Pophali P; Link BK; Habermann TM; Feldman AL
  • Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing.
    ACS Sens Volume: 6 Page(s): 3789 - 3799
    10/22/2021 Authors: Chrit FE; Raj A; Young KM; Stone NE; Shankles PG; Lokireddy K; Flowers C; Waller EK; Alexeev A; Sulchek T
  • Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Leuk Lymphoma Volume: 62 Page(s): 2400 - 2407
    10/01/2021 Authors: Al Feghali KA; Fang P; Gule-Monroe M; Milgrom S; Khoury JD; Gunther JR; Sheu T; Nair R; Ahmed S; Steiner R
  • Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study.
    Haematologica Volume: 106 Page(s): 2774 - 2778
    10/01/2021 Authors: Strati P; De Vos S; Ruan J; Maddocks KJ; Flowers CR; Rule S; Patel P; Xu Y; Wei H; Frigault MM
  • Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
    Cancer Volume: 127 Page(s): 3390 - 3402
    09/15/2021 Authors: Goldman ML; Mao JJ; Strouse CS; Chen W; Rupji M; Chen Z; Maurer MJ; Calzada O; Churnetski M; Flowers CR
  • The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood Volume: 138 Page(s): 785 - 789
    09/02/2021 Authors: Chihara D; Dores GM; Flowers CR; Morton LM
  • Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
    Eur J Haematol Volume: 107 Page(s): 301 - 310
    09/01/2021 Authors: Shanmugasundaram K; Goyal S; Switchenko J; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
  • Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): 36 - 44
    09/01/2021 Authors: Hoppe BS; Advani R; Milgrom SA; Bakst RL; Ballas LK; Dabaja BS; Flowers CR; Ha CS; Mansur DB; Metzger ML
  • Perceptions of clinical care and research among African-American patients with lymphoma.
    Leuk Lymphoma Volume: 62 Page(s): 1860 - 1868
    08/01/2021 Authors: Dance KV; Imbody CB; Chen L; McNeill L; Payne JB; Flowers CR
  • CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
    Blood Adv Volume: 5 Page(s): 2799 - 2806
    07/27/2021 Authors: Greenbaum U; Strati P; Saliba RM; Torres J; Rondon G; Nieto Y; Hosing C; Srour SA; Westin J; Fayad LE
  • Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey.
    Open Forum Infect Dis Volume: 8 Page(s): ofab198
    07/01/2021 Authors: Chang A; Ellingson MK; Flowers CR; Bednarczyk RA
  • Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
    Blood Volume: 137 Page(s): 3272 - 3276
    06/10/2021 Authors: Strati P; Ahmed S; Furqan F; Fayad LE; Lee HJ; Iyer SP; Nair R; Nastoupil LJ; Parmar S; Rodriguez MA
  • The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.
    Leuk Lymphoma Volume: 62 Page(s): 1361 - 1369
    06/01/2021 Authors: Augustyn A; Medeiros LJ; Ludmir EB; Gunther J; Fang P; Li S; Ok CY; Bankston ME; Verma V; Pasalic D
  • Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
    Nat Commun Volume: 12 Page(s): 2877
    05/17/2021 Authors: Zhang S; Jiang VC; Han G; Hao D; Lian J; Liu Y; Cai Q; Zhang R; McIntosh J; Wang R
  • Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
    Am J Hematol Volume: 96 Page(s): 599 - 605
    05/01/2021 Authors: Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D
  • Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria.
    Leuk Lymphoma Volume: 62 Page(s): 1057 - 1065
    05/01/2021 Authors: Ballas LK; Metzger ML; Milgrom SA; Advani R; Bakst RL; Dabaja BS; Flowers CR; Ha CS; Hoppe BS; Mansur DB
  • Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma Volume: 62 Page(s): 1077 - 1087
    05/01/2021 Authors: Wagner-Johnston ND; Schuster SJ; deVos S; Salles G; Jurczak WJ; Flowers CR; Viardot A; Flinn IW; Martin P; Xing G
  • Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
    Am J Hematol Volume: 96 Page(s): E137 - E140
    05/01/2021 Authors: Jain P; Kanagal-Shamanna R; Zhang S; Ok CY; Navsaria L; Nastoupil L; Lee HJ; Tang G; Yin CC; Badillo M
  • Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
    Blood Adv Volume: 5 Page(s): 1737 - 1745
    03/23/2021 Authors: Casulo C; Dixon JG; Ou F-S; Hoster E; Peterson BA; Hochster HS; Brice P; Ladetto M; Hiddemann W; Marcus R
  • Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma.
    Blood Cancer J Volume: 11 Page(s): 2
    01/07/2021 Authors: Merdan S; Subramanian K; Ayer T; Van Weyenbergh J; Chang A; Koff JL; Flowers C
  • Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Br J Haematol Volume: 192 Page(s): e38 - e42
    01/01/2021 Authors: Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W
  • Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
    Volume: 191 Page(s): 806 - 815
    12/01/2020 Authors: Chin CK; Lim KJ; Lewis K; Jain P; Qing Y; Feng L; Cheah CY; Seymour JF; Ritchie D; Burbury K
  • How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
    Leuk Lymphoma Volume: 61 Page(s): 3283 - 3286
    12/01/2020 Authors: Harkins RA; Flowers CR
  • Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.
    Leuk Lymphoma Volume: 61 Page(s): 2985 - 2989
    12/01/2020 Authors: Chin CK; Rodriguez MA; Qing Y; Feng L; Samaniego F; Jain P; Noorani M; Fowler NH; Fayad LE; Westin JR
  • Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
    Blood Adv Volume: 4 Page(s): 5773 - 5784
    11/24/2020 Authors: Noy A; de Vos S; Coleman M; Martin P; Flowers CR; Thieblemont C; Morschhauser F; Collins GP; Ma S; Peles S
  • Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer.
    Oncology (Williston Park) Volume: 34 Page(s): 494 - 499
    11/12/2020 Authors: Payne JB; Flowers CR; Allen PB
  • Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Jain P; Kanagal-Shamanna R; Navsaria L; Ok CY; Hill H; Jung D; Gonzalez GMN; Lee HJ; Nair R; Ahmed S
  • Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age <= 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial
    Volume: 136
    11/05/2020 Authors: Wang M; Jain P; Yao Y; Liu Y; Zhao S; Hill H; Moghrabi O; Lee HJ; Samaniego F; Westin J
  • Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
    Volume: 136
    11/05/2020 Authors: Cherng H-JJ; Steiner RE; Fayad L; Strati P; Nair R; Hagemeister FBB; Nastoupil LJ; Lee HJ; Neelapu SS; Flowers C
  • Body Mass Index and Survival of Patients with Lymphoma
    Volume: 136
    11/05/2020 Authors: Chihara D; Larson MC; Robinson DP; Thompson CA; Maurer MJ; Casulo C; Link BK; Habermann TM; Feldman AL; Flowers C
  • Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Romancik JT; Allen PB; Waller EK; Chen Z; Valla K; Dixon K; Reagan DJ; Colbert AB; Rosand C; Palmer A
  • Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
    Volume: 136
    11/05/2020 Authors: Srour SA; Xu J; Al-Juhaishi T; Steiner RE; Ensor J; Ahmed S; Parmar S; Strati P; Nastoupil LJ; Nieto Y
  • Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis
    Volume: 136
    11/05/2020 Authors: Casulo C; Strawderman M; Delage R; Faugh T; Maurer MJ; Link BK; Rosenthnal AC; Ramsower C; Burack R; Syrbu S
  • Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey
    Volume: 136
    11/05/2020 Authors: Harkins RA; Flowers C
  • Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma
    Volume: 136
    11/05/2020 Authors: Khouri IF; Milton DR; Ledesma C; Jabbour E; Bashir Q; Im JS; Fayad L; Lee HJ; Nair R; Nastoupil LJ
  • Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies
    Volume: 136
    11/05/2020 Authors: Khouri IF; Gruschkus SK; Gulbis A; Ledesma C; Jain N; Kadia TM; Pemmaraju N; Anderlini P; Bashir Q; Daher M
  • Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations
    Volume: 136
    11/05/2020 Authors: Rosenthal K; Abramson JS; Awan FT; Leonard JP; Vose JM; Quill TA; Flowers C
  • Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Srour SA; Nieto Y; Iyer SP; Miranda RN; Maadani F; Rondon G; Saini N; Strati P; Daher M; Nair R
  • Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study
    Volume: 136
    11/05/2020 Authors: Casulo C; Love T; Lu X; Larson MC; Yost KJ; Rosenthal AC; Habermann TM; Link BK; Feldman AL; Slager SL
  • SARS-CoV-2 in multiple myeloma: initial observation and management.
    Leuk Lymphoma Volume: 61 Page(s): 2763 - 2766
    11/01/2020 Authors: Manasanch EE; Mulanovich V; Manzano J-G; Gaeta MS; Becnel M; Kaufman GP; Lee HC; Amini B; Thomas SK; Iyer SP
  • Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 757 - 767.e3
    11/01/2020 Authors: Kudelka MR; Switchenko JM; Lechowicz MJ; Esiashvili N; Flowers CR; Khan MK; Allen PB
  • Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
    Volume: 108 Page(s): S168 - S168
    11/01/2020 Authors: Liu Y; Augustyn A; Gunther JR; Fang P; Nastoupil L; Ahmed S; Strati P; Nair R; Steiner R; Westin J
  • Assessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy
    Volume: 108 Page(s): S116 - S116
    11/01/2020 Authors: Gjyshi O; Boyce-Fappiano D; Gunther JR; Fang P; Nastoupil L; Nair R; Steiner R; Strati P; Ahmed S; Khoury J
  • How Much Did We Impact the Risk of Second Malignancies in Patients with Classical Hodgkin Lymphoma by Changing the Treatment Paradigm?
    Volume: 108 Page(s): S141 - S142
    11/01/2020 Authors: Damron EP; Boyce-Fappiano D; Gunther JR; Pinnix CC; Fang P; Dong W; Lee H; Ahmed S; Strati P; Flowers C
  • Prognostic Value of Disease Location in Secondary Central Nervous System Diffuse Large B-Cell Lymphoma
    Volume: 108 Page(s): E751 - E752
    11/01/2020 Authors: Al Feghali KA; Fang P; Gule-Monroe MK; Khoury J; Gunther JR; Milgrom SA; Sheu T; Nair R; Ahmed S; Steiner R
  • Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes.
    Cancer Epidemiol Biomarkers Prev Volume: 29 Page(s): 1844 - 1855
    10/01/2020 Authors: Moubadder L; McCullough LE; Flowers CR; Koff JL
  • Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.
    JAMA Netw Open Volume: 3 Page(s): e2013935
    09/01/2020 Authors: Pinnix CC; Gunther JR; Fang P; Bankston ME; Milgrom SA; Boyce D; Lee HJ; Nair R; Steiner R; Strati P
  • Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
    CA Cancer J Clin Volume: 70 Page(s): 321 - 346
    09/01/2020 Authors: Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih Y-CT; Walter LC
  • Stiffness based enrichment of leukemia cells using microfluidics.
    APL Bioeng Volume: 4 Page(s): 036101
    09/01/2020 Authors: Islam M; Raj A; McFarland B; Brink HM; Ciciliano J; Fay M; Myers DR; Flowers C; Waller EK; Lam W
  • Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 533 - 541
    08/01/2020 Authors: Glober G; Gunther J; Fang P; Milgrom S; Korivi BR; Jensen CT; Wagner-Bartak NA; Ahmed S; Lee HJ; Nair R
  • Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
    Cancer Volume: 126 Page(s): 3493 - 3503
    08/01/2020 Authors: Lee MJ; Koff JL; Switchenko JM; Jhaney CI; Harkins RA; Patel SP; Dave SS; Flowers CR
  • Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
    Blood Adv Volume: 4 Page(s): 2871 - 2883
    07/14/2020 Authors: Pinnix CC; Gunther JR; Dabaja BS; Strati P; Fang P; Hawkins MC; Adkins S; Westin J; Ahmed S; Fayad L
  • A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma.
    Leuk Lymphoma Volume: 61 Page(s): 1555 - 1564
    07/01/2020 Authors: Allen PB; Ayers A; Behera M; Evens AM; Flowers C
  • Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.
    JCO Glob Oncol Volume: 6 Page(s): 1124 - 1133
    07/01/2020 Authors: Sathyanarayanan V; Flowers CR; Iyer SP
  • Lenalidomide in follicular lymphoma.
    Blood Volume: 135 Page(s): 2133 - 2136
    06/11/2020 Authors: Flowers CR; Leonard JP; Fowler NH
  • Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials.
    Oncology (Williston Park) Volume: 34 Page(s): 216 - 223
    06/10/2020 Authors: Williams S; Ayers AA; Hildebrandt MT; McNeill LH; Flowers CR
  • International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Blood Volume: 135 Page(s): 2041 - 2048
    06/04/2020 Authors: Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M
  • Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Am J Hematol Volume: 95 Page(s): 623 - 629
    06/01/2020 Authors: Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C
  • Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors by race/ethnicity in a multiethnic US population
    Volume: 29
    06/01/2020 Authors: Bolanos R; Hwang A; Aparicio J; Chao C; Qurashi N; Flowers C; Pullarkat S; Conti D; Wang S; Mann K
  • Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
    Leuk Lymphoma Volume: 61 Page(s): 1380 - 1387
    06/01/2020 Authors: Strati P; Ahmed MA; Nastoupil LJ; Feng L; Hagemeister FB; Fayad LE; Rodriguez MA; Samaniego F; Wang M; Westin JR
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
    Lancet Haematol Volume: 7 Page(s): e490 - e497
    06/01/2020 Authors: Thanarajasingam G; Leonard JP; Witzig TE; Habermann TM; Blum KA; Bartlett NL; Flowers CR; Pitcher BN; Jung S-H; Atherton PJ
  • Clinicopathologic features and outcomes of de novo transformed indolent lymphoma.
    Volume: 38
    05/20/2020 Authors: Chin CK; Cheah C; Jain P; Fowler NH; Fayad L; Westin J; Rodriguez MA; Noorani M; Neelapu SS; Hagemeister FB
  • Machine learning prediction of survival in diffuse large B-cell lymphoma based on gene-expression profiling.
    Volume: 38
    05/20/2020 Authors: Merdan S; Subramanian K; Ayer T; Koff JL; Chang A; Van Weyenbergh J; Flowers C
  • MD Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.
    Volume: 38
    05/20/2020 Authors: Nair R; Pinnix CC; Gunther JR; Strati P; Westin J; Fayad L; Hagemeister FB; Iyer SP; Nastoupil LJ; Parmar S
  • MACHINE LEARNING PREDICTION OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA BASED ON GENE-EXPRESSION PROFILING
    Volume: 23 Page(s): S23 - S24
    05/01/2020 Authors: Merdan S; Subramanian K; Ayer T; Weyenbergh J; Koff J; Flowers CR
  • Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia.
    Cancer Volume: 126 Page(s): 1700 - 1707
    04/15/2020 Authors: Clough L; Bayakly AR; Ward KC; Khan MK; Chen SC; Lechowicz MJ; Flowers CR; Allen PB; Switchenko JM
  • The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
    Blood Adv Volume: 4 Page(s): 1407 - 1418
    04/14/2020 Authors: Mato A; Nabhan C; Lamanna N; Kay NE; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Swern AS; Sullivan K
  • Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia.
    Leuk Lymphoma Volume: 61 Page(s): 896 - 904
    04/01/2020 Authors: Lipscomb J; Switchenko JM; Flowers CR; Gillespie TW; Wortley PM; Bayakly AR; Almon L; Fernando R; Ward KC
  • Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 234 - 243.e10
    04/01/2020 Authors: Patel SP; Harkins RA; Lee MJ; Flowers CR; Koff JL
  • Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
    Blood Adv Volume: 4 Page(s): 1038 - 1050
    03/24/2020 Authors: Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer Volume: 126 Page(s): 1235 - 1242
    03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
    J Clin Oncol Volume: 38 Page(s): 496 - 520
    02/10/2020 Authors: Key NS; Khorana AA; Kuderer NM; Bohlke K; Lee AYY; Arcelus JI; Wong SL; Balaban EP; Flowers CR; Francis CW
  • Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    J Clin Oncol Volume: 38 Page(s): 155 - 165
    01/10/2020 Authors: Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M
  • Retroperitoneal Follicular Dendritic Cell Sarcoma: A Case Report.
    Adv Radiat Oncol Volume: 5 Page(s): 297 - 300
    01/01/2020 Authors: Jiang C; Syed YA; Burdette EB; Jaye DL; Flowers CR; Khan MK
  • Priorities for Rural Lymphoma Survivors: A Qualitative Study.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 47 - 52.e3
    01/01/2020 Authors: Chen L; Payne JB; Dance KV; Imbody CB; Ho CD; Ayers AA; Flowers CR
  • Insurance status impacts overall survival in Burkitt lymphoma.
    Volume: 60 Page(s): 3225 - 3234
    12/01/2019 Authors: Goldstein JS; Switchenko JM; Behera M; Flowers CR; Koff JL
  • Cost burden of diffuse large B-cell lymphoma.
    Expert Rev Pharmacoecon Outcomes Res Volume: 19 Page(s): 645 - 661
    12/01/2019 Authors: Harkins RA; Patel SP; Flowers CR
  • Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Blood Volume: 134 Page(s): 1811 - 1820
    11/21/2019 Authors: Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB
  • Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies.
    Int J Cancer Volume: 145 Page(s): 2647 - 2660
    11/15/2019 Authors: Teras LR; Diver WR; Deubler EL; Krewski D; Flowers CR; Switchenko JM; Gapstur SM
  • Patient and caregiver perceptions of lymphoma care and research opportunities: A qualitative study.
    Cancer Volume: 125 Page(s): 4096 - 4104
    11/15/2019 Authors: Payne JB; Dance KV; Farone M; Phan A; Ho CD; Gutierrez M; Chen L; Flowers CR
  • The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient.
    Oncology (Williston Park) Volume: 33
    11/14/2019 Authors: Blanquicett C; Cohen JB; Flowers C; Johnson T
  • Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.
    Blood Volume: 134 Page(s): 19
    11/13/2019 Authors: Li X; Kositsky R; Reddy A; Love C; Naresh K; Koff JL; Nystrand I; Lepp S; Pasanen A; Karjalainen-Lindsberg M-L
  • Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Rosenthal KM; Ansell SM; Leonard JP; Vose JM; Wang ML; Quill TA; Obholz KL; Flowers CR
  • Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
    Volume: 134
    11/13/2019 Authors: Andrie RM; Burke JM; Flowers CR; Fowler NH; Sharman JP; Quill TA; Obholz KL; Flinn IW
  • Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)
    Volume: 134
    11/13/2019 Authors: Maurer MJ; Jakobsen LH; Schmitz N; Farooq U; Flowers CR; Brown PDN; Thompson CA; Frederiksen H; Cunningham D; Jorgensen J
  • Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Cohen JB; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Romancik J; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Epperla N; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group
    Volume: 134
    11/13/2019 Authors: Caglayan C; Dixon J; Wall A; Salles GA; Hoster E; Hiddemann W; Herold M; Morschhauser F; Sebban C; Hagenbeek A
  • Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab
    Volume: 134
    11/13/2019 Authors: Friedberg JW; Brady MT; Strawderman M; Kahl BS; Leonard JP; Lossos IS; Flowers CR; Sutamtewagul G; Cohen JB; Peterson DR
  • Exploring the Needs and Priorities of Black Patients with Lymphoma: A Qualitative Study
    Volume: 134
    11/13/2019 Authors: Dance KV; Chen L; Imbody CB; Flowers CR
  • The whole-genome landscape of Burkitt lymphoma subtypes.
    Blood Volume: 134 Page(s): 1598 - 1607
    11/07/2019 Authors: Panea RI; Love CL; Shingleton JR; Reddy A; Bailey JA; Moormann AM; Otieno JA; Ong'echa JM; Oduor CI; Schroeder KMS
  • Dual inhibition of PI3Kdelta and PI3Kgamma to enhance mitochondrial mass and ex vivo expansion of central and stem cell memory T cells from CLL patients
    Volume: 7
    11/06/2019 Authors: Funk C; Wang S; Waller A; Fleischer L; Sharma A; Spencer H; Gupta V; Ravindranathan S; Shanmugam M; Flowers C
  • Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
    Expert Rev Hematol Volume: 12 Page(s): 959 - 973
    11/01/2019 Authors: Harkins RA; Chang A; Patel SP; Lee MJ; Goldstein JS; Merdan S; Flowers CR; Koff JL
  • Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 699 - 708.e5
    11/01/2019 Authors: Ayers AA; Lyu L; Dance K; Ward KC; Flowers CR; Koff JL; McCullough LE
  • Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection.
    Clin Cancer Res Volume: 25 Page(s): 6283 - 6294
    11/01/2019 Authors: Aleynick M; Svensson-Arvelund J; Flowers CR; Marabelle A; Brody JD
  • Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.
    Leuk Lymphoma Volume: 60 Page(s): 2356 - 2364
    10/01/2019 Authors: Zackon AYL; Ayers AA; Yeager KA; Somma ML; Friedberg JW; Flowers CR; Nastoupil LJ
  • Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.
    Volume: 60 Page(s): 2255 - 2263
    09/01/2019 Authors: Gopalsamy SN; Rosenthal KM; Ayers AA; Goy A; Leonard JP; Vose JM; Obholz KL; Armitage JO; Flowers CR
  • PET-derived tumor metrics predict DLBCL response and progression-free survival.
    Volume: 60 Page(s): 1965 - 1971
    08/01/2019 Authors: Islam P; Goldstein J; Flowers CR
  • Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.
    Leuk Lymphoma Volume: 60 Page(s): 1656 - 1667
    07/01/2019 Authors: Ritter AJ; Goldstein JS; Ayers AA; Flowers CR
  • Examining genetic ancestry in diffuse large B-cell lymphoma (DLBCL)
    Volume: 79
    07/01/2019 Authors: Lee MJ; Jhaney CI; Flowers CR; Koff JL
  • Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors is explained by histologic subtype, not race/ethnicity in a multiethnic US population
    Volume: 79
    07/01/2019 Authors: Bolanos R; Hwang A; Chao C; Flowers C; Pullarkat S; Aparicio J; Wang S; Mann K; Bernal-Mizrachi L; Song J
  • A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
    Cancer Volume: 125 Page(s): 1837 - 1847
    06/01/2019 Authors: alayan ; Goldstein JS; Ayer T; Rai A; Flowers CR
  • Racial and Socioeconomic Disparities in Mantle Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): e312 - e320
    06/01/2019 Authors: Shah NN; Xi Y; Liu Y; Koff JL; Flowers CR; Behera M; Cohen JB
  • Impact on survival of surveillance imaging after first remission in follicular lymphoma.
    Volume: 37
    05/20/2019 Authors: Mao J; Strouse CS; Goldman M; Chen W; Chen Z; Maurer MJ; Calzada O; Churnetski M; Flowers C; Cerhan JR
  • Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene and trichloroethylene
    Volume: 37
    05/20/2019 Authors: Allen PB; Clough L; Bayakly AR; Ward KC; Khan MK; Chen S; Flowers C; Switchenko JM
  • Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 300 - 309.e5
    05/01/2019 Authors: alayan ; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
  • Reply to M.A. Slavin et al.
    J Clin Oncol Volume: 37 Page(s): 1140 - 1141
    05/01/2019 Authors: Taplitz RA; Kennedy EB; Flowers CR
  • Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
    Volume: 60 Page(s): 940 - 946
    04/01/2019 Authors: Badar T; Hamadani M; Bachanova V; Maddocks KJ; Umyarova E; Chavez JC; Epperla N; Chhabra S; Xavier AC; Karmali R
  • Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
    Leuk Lymphoma Volume: 60 Page(s): 894 - 903
    04/01/2019 Authors: Sharman JP; Forero-Torres A; Costa LJ; Flinn IW; Inhorn L; Kelly K; Bessudo A; Fayad LE; Kaminski MS; Evens AM
  • Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 239 - 243
    04/01/2019 Authors: Chang A; Payne JB; Allen PB; Koff JL; Ahmed R; Flowers CR; Bednarczyk RA
  • Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Volume: 185 Page(s): 80 - 80
    03/01/2019 Authors: McMillan A; Sehn L; Herrera A; Matasar M; Kamdar M; Assouline S; Hertzberg M; Kim TM; Kim WS; Ozcan M
  • Epstein-Barr Virus prevalence in classic Hodgkin lymphoma is predicted by histologic subtype and not race or ethnicity a multiethnic US cohort
    Volume: 32
    03/01/2019 Authors: Bolanos R; Hwang A; Chao C; Flowers C; Pullarkat S; Aparicio J; Wang S; Mann K; Bernal-Mizrachi L; Song J
  • Epstein-Barr Virus prevalence in classic Hodgkin lymphoma is predicted by histologic subtype and not race or ethnicity a multiethnic US cohort
    Volume: 99
    03/01/2019 Authors: Bolanos R; Hwang A; Chao C; Flowers C; Pullarkat S; Aparicio J; Wang S; Mann K; Bernal-Mizrachi L; Song J
  • Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation
    Volume: 25
    03/01/2019 Authors: Churnetski MC; Switchenko JM; Goyal S; Shanmugasundaram K; Calzada O; Kolla B; Bachanova V; Gerson JN; Barta SK; Maldonado E
  • Reply to H.J.A. Adams et al.
    J Clin Oncol Volume: 37 Page(s): 526 - 527
    02/20/2019 Authors: Shi Q; Flowers CR
  • Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Lancet Haematol Volume: 6 Page(s): e100 - e109
    02/01/2019 Authors: Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S
  • Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.
    Volume: 19 Page(s): 89 - 94
    02/01/2019 Authors: Hall KH; Valla K; Flowers CR; Cohen JB
  • Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.
    Br J Haematol Volume: 184 Page(s): 660 - 663
    02/01/2019 Authors: Link BK; Day B-M; Zhou X; Zelenetz AD; Dawson KL; Cerhan JR; Flowers CR; Friedberg JW
  • Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Cancer Volume: 125 Page(s): 185 - 193
    01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR
  • Autograft vs Allograft Comparison in Pediatric Medial Patellofemoral Ligament Reconstruction.
    Ochsner J Volume: 19 Page(s): 96 - 101
    01/01/2019 Authors: Hendawi T; Godshaw B; Flowers C; Stephens I; Haber L; Waldron S
  • Clinical Implications of Febrile Neutropenia Guidelines in the Cancer Patient Population.
    J Oncol Pract Volume: 15 Page(s): 25 - 26
    01/01/2019 Authors: Braga CC; Taplitz RA; Flowers CR
  • Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.
    Cancer J Volume: 25 Page(s): 418 - 427
    01/01/2019 Authors: Harkins RA; Patel SP; Flowers CR
  • Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Volume: 42 Page(s): 3 - 3
    01/01/2019 Authors: Glass B; Sehn LH; Herrera AF; Matasar M; Kamdar M; Assouline S; Hertzberg M; Kim TM; Kim WS; McMillan A
  • Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
    Int J Mol Sci Volume: 19
    12/19/2018 Authors: Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
  • Microsimulation Modeling in Oncology.
    JCO Clin Cancer Inform Volume: 2 Page(s): 1 - 11
    12/01/2018 Authors: alayan ; Terawaki H; Chen Q; Rai A; Ayer T; Flowers CR
  • Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
    Leuk Lymphoma Volume: 59 Page(s): 2862 - 2870
    12/01/2018 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover N; Mathews S; Park SI; Gordon M; Danilov A; Epperla N
  • The association of physical activity before and after lymphoma diagnosis with survival outcomes.
    Am J Hematol Volume: 93 Page(s): 1543 - 1550
    12/01/2018 Authors: Pophali PA; Ip A; Larson MC; Rosenthal AC; Maurer MJ; Flowers CR; Link BK; Farooq U; Feldman AL; Allmer C
  • Novel immunotherapy approaches to follicular lymphoma.
    Hematology Am Soc Hematol Educ Program Volume: 2018 Page(s): 194 - 199
    11/30/2018 Authors: Flowers CR; Leonard JP; Nastoupil LJ
  • Sequencing of therapies in relapsed follicular lymphoma.
    Hematology Am Soc Hematol Educ Program Volume: 2018 Page(s): 189 - 193
    11/30/2018 Authors: Nastoupil LJ; Flowers CR; Leonard JP
  • Where to start? Upfront therapy for follicular lymphoma in 2018.
    Hematology Am Soc Hematol Educ Program Volume: 2018 Page(s): 185 - 188
    11/30/2018 Authors: Leonard JP; Nastoupil LJ; Flowers CR
  • Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-kappa B Pathway
    Volume: 132
    11/29/2018 Authors: Cinar M; Rong H-R; Chineke I; Louissaint A; Chapman-Fredricks JR; Vega F; Gunthel CJ; Love C; Mosunjac M; Flowers CR
  • Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy
    Volume: 132
    11/29/2018 Authors: Kudelka M; Lechowicz MJ; Khan MK; Esiashvili N; Flowers CR; Allen P
  • The need to assess financial adverse events.
    Lancet Haematol Volume: 5 Page(s): e508 - e509
    11/01/2018 Authors: Nastoupil LJ; Prasad V; Flowers CR
  • In Patients Over 65, Consolidative Radiation for Early Stage Diffuse Large B Cell Lymphoma is Associated with Decreased Hematologic Toxicity and Hospitalizations after RCHOP Compared with RCHOP Alone
    Volume: 102 Page(s): S190 - S190
    11/01/2018 Authors: Madden NA; Danish H; Cassidy RJ; Abugideiri M; Switchenko J; Rai A; Flowers CR; Esiashvili N; Jegadeesh N; Khan MK
  • Consolidative Radiation Therapy (RT) for Advanced Stage Hodgkin's Lymphoma (HL) May Improve Progression Free Survival Than ABVD Alone for Adult Patients.
    Volume: 102 Page(s): E280 - E280
    11/01/2018 Authors: Subramanian K; Switchenko J; Flowers CR; Esiashvili N; Khan MK
  • Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States.
    Br J Haematol Volume: 183 Page(s): 385 - 399
    11/01/2018 Authors: Blum KA; Keller FG; Castellino S; Phan A; Flowers CR
  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.
    J Oncol Pract Volume: 14 Page(s): 692 - 695
    11/01/2018 Authors: Taplitz RA; Kennedy EB; Flowers CR
  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
    J Clin Oncol Volume: 36 Page(s): 3043 - 3054
    10/20/2018 Authors: Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston KV
  • What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
    J Clin Oncol Page(s): JCO2018793570
    10/02/2018 Authors: Flowers CR; Ramsey SD
  • Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect CLL cohort study.
    Leuk Lymphoma Volume: 59 Page(s): 2327 - 2335
    10/01/2018 Authors: Flowers CR; Nabhan C; Kay NE; Mato A; Lamanna N; Farber CM; Davids MS; Kiselev P; Swern AS; Sullivan K
  • Disparities in survival by insurance status in follicular lymphoma.
    Blood Volume: 132 Page(s): 1159 - 1166
    09/13/2018 Authors: Goldstein JS; Nastoupil LJ; Han X; Jemal A; Ward E; Flowers CR
  • Reply to J.A. Talcott.
    J Clin Oncol Page(s): JCO2018793141
    09/04/2018 Authors: Taplitz RA; Kennedy EB; Flowers CR
  • Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    Ann Oncol Volume: 29 Page(s): 1932 - 1938
    09/01/2018 Authors: de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM
  • A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 18 Page(s): 569 - 575.e1
    09/01/2018 Authors: Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R
  • Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    J Clin Oncol Volume: 36 Page(s): 2593 - 2602
    09/01/2018 Authors: Shi Q; Schmitz N; Ou F-S; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C
  • Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer.
    JAMA Netw Open Volume: 1 Page(s): e181243
    08/03/2018 Authors: McCullough LE; Flowers CR
  • History of autoimmune conditions and lymphoma prognosis.
    Blood Cancer J Volume: 8 Page(s): 73
    08/01/2018 Authors: Kleinstern G; Maurer MJ; Liebow M; Habermann TM; Koff JL; Allmer C; Witzig TE; Nowakowski GS; Micallef IN; Johnston PB
  • Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
    Ann Oncol Volume: 29 Page(s): 1822 - 1827
    08/01/2018 Authors: Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H
  • HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.
    Cancer Res Volume: 78 Page(s): 4086 - 4096
    07/15/2018 Authors: Wang SS; Carrington M; Berndt SI; Slager SL; Bracci PM; Voutsinas J; Cerhan JR; Smedby KE; Hjalgrim H; Vijai J
  • Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Leuk Lymphoma Volume: 59 Page(s): 1700 - 1709
    07/01/2018 Authors: Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
  • Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.
    CA Cancer J Clin Volume: 68 Page(s): 250 - 281
    07/01/2018 Authors: Wolf AMD; Fontham ETH; Church TR; Flowers CR; Guerra CE; LaMonte SJ; Etzioni R; McKenna MT; Oeffinger KC; Shih Y-CT
  • Impact of the posttransplant lymphoproliferative disorder subtype on survival.
    Cancer Volume: 124 Page(s): 2327 - 2336
    06/01/2018 Authors: Koff JL; Li J-X; Zhang X; Switchenko JM; Flowers CR; Waller EK
  • Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Cancer Volume: 124 Page(s): 2306 - 2315
    06/01/2018 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ
  • Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors.
    Cancer Causes Control Volume: 29 Page(s): 551 - 561
    06/01/2018 Authors: Keegan THM; Li Q; Steele A; Alvarez EM; Brunson A; Flowers CR; Glaser SL; Wun T
  • Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database.
    Br J Haematol Volume: 181 Page(s): 721 - 722
    06/01/2018 Authors: Feldman AL; Flowers CR
  • Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
    Expert Opin Investig Drugs Volume: 27 Page(s): 513 - 522
    06/01/2018 Authors: Valla K; Flowers CR; Koff JL
  • Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
    Biol Blood Marrow Transplant Volume: 24 Page(s): 1163 - 1171
    06/01/2018 Authors: Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI
  • How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
    Oncology (Williston Park) Volume: 32 Page(s): 303 - 309
    06/01/2018 Authors: Hall KH; Panjic EH; Valla K; Flowers CR; Cohen JB
  • Racial and socioeconomic disparities in mantle cell lymphoma.
    Volume: 36
    05/20/2018 Authors: Shah N; Liu Y; Xi Y; Flowers C; Koff JL; Behera M; Cohen JB
  • Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
    Volume: 36
    05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
  • ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.
    Volume: 36
    05/20/2018 Authors: Brady M; Strawderman MS; Flowers C; Kahl BS; Leonard JP; Nastoupil LJ; Witzig TE; Peterson DR; Friedberg JW
  • A meta-analysis on ABVD administration in HIV plus patients with advanced stage Hodgkin's lymphoma (HL).
    Volume: 36
    05/20/2018 Authors: Subramanian K; Switchenko JM; Flowers C; Khan MK
  • Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).
    Volume: 36
    05/20/2018 Authors: Calzada O; Xi Y; Behera M; Koff JL; Flowers C; Liu Y; Cohen JB
  • Association of insurance status and race with overall survival among patients with cutaneous T-cell lymphoma: A National Cancer DataBase analysis.
    Volume: 36
    05/20/2018 Authors: Allen PB; Flowers C; Lechowicz MJ; Goldstein J
  • Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.
    Volume: 36
    05/20/2018 Authors: Fama A; Martin P; Casulo C; Nastoupil LJ; Thompson CA; Link BK; Lossos IS; Kahl B; Maurer M; Allmer C
  • Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.
    J Clin Oncol Volume: 36 Page(s): 1443 - 1453
    05/10/2018 Authors: Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston K
  • Effective management strategies for patients with marginal zone lymphoma.
    Future Oncol Volume: 14 Page(s): 1213 - 1222
    05/01/2018 Authors: Rosand CB; Valla K; Flowers CR; Koff JL
  • Balancing patient value and payer cost in hematologic malignancies: can it be done?
    Expert Rev Pharmacoecon Outcomes Res Volume: 18 Page(s): 123 - 126
    04/01/2018 Authors: Allen PB; Flowers CR
  • Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary.
    J Oncol Pract Volume: 14 Page(s): 250 - 255
    04/01/2018 Authors: Taplitz RA; Kennedy EB; Flowers CR
  • Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Leuk Lymphoma Volume: 59 Page(s): 888 - 895
    04/01/2018 Authors: Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
  • Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma.
    Volume: 36
    03/01/2018 Authors: Ip A; Pophali PA; Larson MC; Rosenthal AC; Maurer MJ; Link BK; Farooq U; Feldman AL; Allmer C; Slager SL
  • Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180-2185.
    Blood Volume: 131 Page(s): 1037
    03/01/2018
  • Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
    Volume: 24 Page(s): S135 - S136
    03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S
  • Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K inhibitors and VIP antagonists.
    Blood Adv Volume: 2 Page(s): 210 - 223
    02/13/2018 Authors: Petersen CT; Hassan M; Morris AB; Jeffery J; Lee K; Jagirdar N; Staton AD; Raikar SS; Spencer HT; Sulchek T
  • Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Clin Lymphoma Myeloma Leuk Volume: 18 Page(s): 114 - 124.e2
    02/01/2018 Authors: Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P
  • Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.
    Volume: 18 Page(s): e115 - e121
    02/01/2018 Authors: Koff JL; Rai A; Flowers CR
  • Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies.
    JCO Clin Cancer Inform Volume: 2
    01/01/2018 Authors: Jordan J; Goldstein JS; Jaye DL; Gurcan M; Flowers CR; Cooper LAD
  • Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
    Expert Opin Investig Drugs Volume: 27 Page(s): 55 - 70
    01/01/2018 Authors: Chang A; Schlafer D; Flowers CR; Allen PB
  • When to Choose Transplant in Follicular Lymphoma: Navigating a Complex Landscape.
    J Oncol Pract Volume: 13 Page(s): 808 - 809
    12/01/2017 Authors: Casulo C; Flowers CR
  • The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.
    Oncologist Volume: 22 Page(s): 1415 - 1418
    12/01/2017 Authors: Sargent DJ; Shi Q; Flowers CR; Schmitz N; Habermann TM; Flament J; Fu T; Coiffier B; SEAL group
  • Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.
    Blood Adv Volume: 1 Page(s): 2433 - 2443
    11/28/2017 Authors: Ahn IE; Farber CM; Davids MS; Grinblatt DL; Kay NE; Lamanna N; Mato A; Nabhan C; Kiselev P; Swern AS
  • Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.
    Blood Volume: 130 Page(s): 2180 - 2185
    11/16/2017 Authors: Lin RJ; Behera M; Diefenbach CS; Flowers CR
  • C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Cancer Volume: 123 Page(s): 4411 - 4418
    11/15/2017 Authors: Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M
  • Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.
    Ann Lymphoma Volume: 1
    11/01/2017 Authors: Becnel M; Flowers CR; Nastoupil LJ
  • Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol Volume: 35 Page(s): 3538 - 3546
    11/01/2017 Authors: Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ
  • Genetic and Functional Drivers of Diffuse Large BCell Lymphoma.
    Cell Volume: 171 Page(s): 481 - 494.e15
    10/05/2017 Authors: Reddy A; Zhang J; Davis NS; Moffitt AB; Love CL; Waldrop A; Leppa S; Pasanen A; Meriranta L; Karjalainen-Lindsberg M-L
  • Reply to . Benedict et al.
    J Clin Oncol Volume: 35 Page(s): 3086 - 3087
    09/10/2017 Authors: Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
  • Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.
    J Clin Oncol Volume: 35 Page(s): 3075 - 3082
    09/10/2017 Authors: Polite BN; Adams-Campbell LL; Brawley OW; Bickell N; Carethers JM; Flowers CR; Foti M; Gomez SL; Griggs JJ; Lathan CS
  • A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 58 Page(s): 1 - 2
    09/01/2017 Authors: Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
  • Unmet needs in the first-line treatment of follicular lymphoma.
    Ann Oncol Volume: 28 Page(s): 2094 - 2106
    09/01/2017 Authors: Casulo C; Nastoupil L; Fowler NH; Friedberg JW; Flowers CR
  • Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
    Cancer Volume: 123 Page(s): 3222 - 3225
    09/01/2017 Authors: Koff JL; Flowers CR
  • The importance of immunization in cancer prevention, treatment, and survivorship.
    CA Cancer J Clin Volume: 67 Page(s): 398 - 410
    09/01/2017 Authors: Ward EM; Flowers CR; Gansler T; Omer SB; Bednarczyk RA
  • Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.
    Cancer Res Volume: 77 Page(s): 4548 - 4555
    09/01/2017 Authors: Polite BN; Adams-Campbell LL; Brawley OW; Bickell N; Carethers JM; Flowers CR; Foti M; Gomez SL; Griggs JJ; Lathan CS
  • Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.
    CA Cancer J Clin Volume: 67 Page(s): 353 - 361
    09/01/2017 Authors: Polite BN; Adams-Campbell LL; Brawley OW; Bickell N; Carethers JM; Flowers CR; Foti M; Gomez SL; Griggs JJ; Lathan CS
  • Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities
    Volume: 17 Page(s): S377 - S377
    09/01/2017 Authors: Greenwell IB; Staton AD; Lee M; Switchenko JM; Maly J; Blum K; Grover N; Mathews S; Park S; Gordon M
  • American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce.
    J Clin Oncol Volume: 35 Page(s): 2576 - 2579
    08/01/2017 Authors: Winkfield KM; Flowers CR; Patel JD; Rodriguez G; Robinson P; Agarwal A; Pierce L; Brawley OW; Mitchell EP; Head-Smith KT
  • Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
    Oncogene Volume: 36 Page(s): 4224 - 4232
    07/20/2017 Authors: Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP
  • Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.
    Volume: 23 Page(s): 1117 - 1121
    07/01/2017 Authors: Hamilton BK; Rybicki L; Abounader D; Adekola K; Advani A; Aldoss I; Bachanova V; Bashey A; Brown S; DeLima M
  • Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol Volume: 178 Page(s): 72 - 80
    07/01/2017 Authors: Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
  • Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.
    Leuk Lymphoma Volume: 58 Page(s): 1570 - 1580
    07/01/2017 Authors: Rai A; Nastoupil LJ; Williams JN; Lipscomb J; Ward KC; Howard DH; Lee D; Flowers CR
  • CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
    Volume: 102 Page(s): 312 - 312
    06/26/2017 Authors: Nastoupil L; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S
  • Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.
    Infect Control Hosp Epidemiol Volume: 38 Page(s): 651 - 657
    06/01/2017 Authors: Shah NN; McClellan W; Flowers CR; Lonial S; Khoury H; Waller EK; Langston A; Nooka AK
  • Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood Volume: 129 Page(s): 3037 - 3039
    06/01/2017 Authors: Gopal AK; Kahl BS; Flowers CR; Martin P; Ansell SM; Abella-Dominicis E; Koh B; Ye W; Barr PM; Salles GA
  • Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.
    J Gastrointest Oncol Volume: 8 Page(s): 513 - 523
    06/01/2017 Authors: Zeichner SB; Goldstein DA; Kohn C; Flowers CR
  • Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.
    Oncologist Volume: 22 Page(s): 694 - 699
    06/01/2017 Authors: Goldstein DA; Chen Q; Ayer T; Chan KKW; Virik K; Hammerman A; Brenner B; Flowers CR; Hall PS
  • Reply to C. Nabhan et al.
    J Clin Oncol Volume: 35 Page(s): 1864 - 1865
    06/01/2017 Authors: Chen Q; Jain N; Flowers CR; Chhatwal J
  • A multistate model for follicular lymphoma (FL) patients (pts) who experience early progression.
    Volume: 35
    05/20/2017 Authors: Terawaki H; Caglayan C; Chen Q; Rai A; Ayer T; Flowers C
  • Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.
    Volume: 35
    05/20/2017 Authors: Nastoupil LJ; Lunning MA; Vose J; Schreeder MT; Siddiqi T; Flowers C; Cohen JB; Burger JA; Wierda WG; O'Brien SM
  • MYC plus relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
    Volume: 35
    05/20/2017 Authors: Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy NM; Karmali R; Umyarova E; Bachanova V; Glenn MJ; Xavier AC
  • Interim metabolic tumor volume to predict response in diffuse large B-cell lymphoma.
    Volume: 35
    05/20/2017 Authors: Islam P; Goldstein J; Sethi I; Lee D; Flowers C
  • THE COST-EFFECTIVENESS OF PRECISION MEDICINE TREATMENT STRATEGIES FOR DIFFUSE LARGE B-CELL LYMPHOMA
    Volume: 20 Page(s): A107 - A107
    05/01/2017 Authors: Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
  • Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood Volume: 129 Page(s): 2224 - 2232
    04/20/2017 Authors: Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S
  • Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol Volume: 35 Page(s): 1194 - 1202
    04/10/2017 Authors: Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
  • [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
    Leuk Lymphoma Volume: 58 Page(s): 809 - 815
    04/01/2017 Authors: Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
  • Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
    Haematologica Volume: 102 Page(s): e156 - e159
    04/01/2017 Authors: Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Blum KA; Flowers CR; Jurczak WJ; Flinn IW; Kahl BS
  • The Genetic Basis of Hepatosplenic T-cell Lymphoma.
    Cancer Discov Volume: 7 Page(s): 369 - 379
    04/01/2017 Authors: McKinney M; Moffitt AB; Gaulard P; Travert M; De Leval L; Nicolae A; Raffeld M; Jaffe ES; Pittaluga S; Xi L
  • Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
    BMC Cancer Volume: 17 Page(s): 198
    03/16/2017 Authors: Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K
  • HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy.
    Cancer Epidemiol Biomarkers Prev Volume: 26 Page(s): 303 - 311
    03/01/2017 Authors: Han X; Jemal A; Hulland E; Simard EP; Nastoupil L; Ward E; Flowers CR
  • Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Expert Rev Anticancer Ther Volume: 17 Page(s): 271 - 279
    03/01/2017 Authors: Greenwell IB; Flowers CR; Blum KA; Cohen JB
  • Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1
    Volume: 23 Page(s): S215 - S216
    03/01/2017 Authors: Greenwell IB; Valla K; Caulfield S; Switchenko JM; Staton A; Flowers C; Maly J; Blum KA; Grover N; Mathews S
  • Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
    J Clin Oncol Volume: 35 Page(s): 552 - 560
    02/10/2017 Authors: Shi Q; Flowers CR; Hiddemann W; Marcus R; Herold M; Hagenbeek A; Kimby E; Hochster H; Vitolo U; Peterson BA
  • Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Blood Volume: 129 Page(s): 561 - 564
    02/02/2017 Authors: Cohen JB; Behera M; Thompson CA; Flowers CR
  • Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
    Am J Hematol Volume: 92 Page(s): 161 - 170
    02/01/2017 Authors: Costa LJ; Maddocks K; Epperla N; Reddy NM; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn MJ; Chavez JC
  • Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
    J Clin Oncol Volume: 35 Page(s): 166 - 174
    01/10/2017 Authors: Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
  • Making the Case for Improving Oncology Workforce Diversity.
    Am Soc Clin Oncol Educ Book Volume: 37 Page(s): 18 - 22
    01/01/2017 Authors: Winkfield KM; Flowers CR; Mitchell EP
  • Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
    Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
    01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
  • ACR Appropriateness Criteria Recurrent Hodgkin Lymphoma.
    Oncology (Williston Park) Volume: 30 Page(s): 1099 - 1108
    12/15/2016 Authors: Winkfield KM; Advani RH; Ballas LK; Dabaja BS; Dhakal S; Flowers CR; Ha CS; Hoppe BS; Mansur DB; Mendenhall NP
  • Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect (R) CLL Registry
    Volume: 128
    12/02/2016 Authors: Ahn IE; Farber CM; Davids M; Grinblatt DL; Lamanna N; Mato AR; Nabhan C; Kiselev P; Swern AS; Flick ED
  • Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant
    Volume: 128
    12/02/2016 Authors: Kettle AG; Switchenko J; Calzada O; Anh TP; Farone M; Graiser M; Flowers CR; Cohen JB
  • Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect (R) CLL Registry
    Volume: 128
    12/02/2016 Authors: Sharman J; Davids M; Farber CM; Grinblatt DL; Kay NE; Lamanna N; Mato AR; Nabhan C; Sullivan K; Flick ED
  • Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
    Volume: 128
    12/02/2016 Authors: Lewis SJ; Goldstein J; Farone M; Anh TP; Koff JL; Staton AD; Mobadersany P; Cooper L; Flowers C
  • CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma
    Volume: 128
    12/02/2016 Authors: Calzada O; Bradley KT; Switchenko J; Staton AD; Koff JL; Flowers CR; Cohen JB
  • An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission
    Volume: 128
    12/02/2016 Authors: Guidot DM; Switchenko J; Nastoupil LJ; Koff JL; Flowers C; Cohen JB
  • Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics
    Volume: 128
    12/02/2016 Authors: Staton AD; Greenwell IB; Switchenko JM; Maly J; Blum K; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV
  • a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Volume: 128
    12/02/2016 Authors: Maddocks KJ; Cohen JB; Huang Y; Christian BA; Benson DM; Jones J; Flowers C; Heffner LT; Jenkins C; Sexton J
  • Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features
    Volume: 128
    12/02/2016 Authors: Costa LJ; Reddy N; Maddocks KJ; Epperla N; Karmali R; Bachanova V; Umyarova E; Zhou Z; Glenn M; Chavez JC
  • Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study
    Volume: 128
    12/02/2016 Authors: Flowers C; Ou F-S; Shi Q; Hoster E; Peterson BA; Hochster HS; Brice P; Ladetto M; Hiddemann W; Marcus RE
  • Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin Lymphoma
    Volume: 128
    12/02/2016 Authors: Keegan T; Li Q; Steele A; Alvarez E; Brunson AM; Flowers C; Glaser SL; Wun T
  • Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
    Volume: 128
    12/02/2016 Authors: Lewis SJ; Goldstein J; Farone M; Anh TP; Koff JL; Staton AD; Mobadersany P; Cooper L; Flowers C
  • Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.
    Br J Haematol Volume: 175 Page(s): 892 - 903
    12/01/2016 Authors: Mato A; Nabhan C; Kay NE; Weiss MA; Lamanna N; Kipps TJ; Grinblatt DL; Flinn IW; Kozloff MF; Flowers CR
  • ACR Appropriateness Criteria Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
    Am J Clin Oncol Volume: 39 Page(s): 535 - 544
    12/01/2016 Authors: Dhakal S; Advani R; Ballas LK; Dabaja BS; Flowers CR; Ha CS; Hoppe BS; Mendenhall NP; Metzger ML; Plastaras JP
  • Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Szary syndrome.
    Leuk Lymphoma Volume: 57 Page(s): 2813 - 2819
    12/01/2016 Authors: Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
  • 2016 US lymphoid malignancy statistics by World Health Organization subtypes.
    CA Cancer J Clin Volume: 66 Page(s): 443 - 459
    11/12/2016 Authors: Teras LR; DeSantis CE; Cerhan JR; Morton LM; Jemal A; Flowers CR
  • Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
    Immunotherapy Volume: 8 Page(s): 1335 - 1346
    11/01/2016 Authors: Marron TU; Ronner L; Martin PE; Flowers CR; Brody JD
  • Consolidative Radiation for Early-Stage Diffuse Large B Cell Lymphoma After CHOP or RCHOP: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis
    Volume: 96 Page(s): E499 - E499
    10/01/2016 Authors: Danish H; Cassidy RJ; Switchenko JM; Rai A; Jegadeesh N; Flowers CR; Esiashvili N; Khan MK
  • Validation of Cutaneous Lymphoma International Prognostic Index (CLIPI) for Mycosis Fungoides and Sezary Syndrome
    Volume: 96 Page(s): S165 - S166
    10/01/2016 Authors: Jhaveri J; Danish H; Liu S; Flowers CR; Lechwoicz MJ; Patel K; Esiashvili N; Khan MK
  • Consolidative Radiation for Early-Stage Diffuse Large B Cell Lymphoma After CHOP or RCHOP: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis
    Volume: 96 Page(s): E499 - E499
    10/01/2016 Authors: Danish H; Cassidy RJ; Switchenko JM; Rai A; Jegadeesh N; Flowers CR; Esiashvili N; Khan MK
  • Validation of Cutaneous Lymphoma International Prognostic Index (CLIPI) for Mycosis Fungoides and Sezary Syndrome
    Volume: 96 Page(s): S165 - S166
    10/01/2016 Authors: Jhaveri J; Danish H; Liu S; Flowers CR; Lechwoicz MJ; Patel K; Esiashvili N; Khan MK
  • Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence.
    South Med J Volume: 109 Page(s): 606 - 614
    10/01/2016 Authors: Bulka C; Nastoupil LJ; Koff JL; Bernal-Mizrachi L; Ward KC; Williams JN; Bayakly AR; Switchenko JM; Waller LA; Flowers CR
  • Consolidative Radiation for Early-Stage Diffuse Large B Cell Lymphoma After CHOP or RCHOP: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E499
    10/01/2016 Authors: Danish H; Cassidy RJ; Switchenko JM; Rai A; Jegadeesh N; Flowers CR; Esiashvili N; Khan MK
  • Validation of Cutaneous Lymphoma International Prognostic Index (CLIPI) for Mycosis Fungoides and Sezary Syndrome.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S165 - S166
    10/01/2016 Authors: Jhaveri J; Danish H; Liu S; Flowers CR; Lechwoicz MJ; Patel K; Esiashvili N; Khan MK
  • The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
    Leuk Lymphoma Volume: 57 Page(s): 1876 - 1882
    08/01/2016 Authors: Cassidy RJ; Jegadeesh N; Switchenko J; Danish H; Esiashvili N; Flowers CR; Khan MK
  • Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
    Volume: 122 Page(s): 2356 - 2363
    08/01/2016 Authors: Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
  • ACR Appropriateness Criteria Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
    Am J Clin Oncol Volume: 39 Page(s): 384 - 395
    08/01/2016 Authors: Roberts KB; Younes A; Hodgson DC; Advani R; Dabaja BS; Dhakal S; Flowers CR; Ha CS; Hoppe BS; Mendenhall NP
  • Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 466 - 471.e1
    08/01/2016 Authors: DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R
  • Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
    Am J Hematol Volume: 91 Page(s): 770 - 775
    08/01/2016 Authors: Nabhan C; Zhou X; Day B-M; Dawson K; Zelenetz AD; Friedberg JW; Cerhan JR; Link BK; Flowers CR
  • Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Biol Blood Marrow Transplant Volume: 22 Page(s): 1197 - 1205
    07/01/2016 Authors: Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC
  • Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma.
    Ann Thorac Surg Volume: 102 Page(s): 304 - 305
    07/01/2016 Authors: Moss E; Goldstein DA; Bradley KT; Flowers CR; Murphy DA
  • LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB
    Volume: 101 Page(s): 50 - 51
    06/01/2016 Authors: Mato A; Burris HA; Flinn I; Lunning M; Vose J; Fowler N; Nastoupil L; O'Brien S; Schreeder MT; Patel MR
  • LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB
    Volume: 101 Page(s): 102 - 103
    06/01/2016 Authors: O'Connor OA; Flinn I; Lunning M; Vose J; Fowler N; Nastoupil L; O'Brien S; Schreeder MT; Patel MR; Fenske TS
  • CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.
    Dermatol Ther (Heidelb) Volume: 6 Page(s): 251 - 263
    06/01/2016 Authors: Danish HH; Heumann TR; Bradley KT; Switchenko J; Esiashvili N; Lechowicz MJ; Flowers CR; Khan MK
  • B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.
    Expert Rev Hematol Volume: 9 Page(s): 553 - 561
    06/01/2016 Authors: Koff JL; Flowers CR
  • Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era.
    Volume: 34
    05/20/2016 Authors: Keegan THM; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers C; Tao L
  • Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma
    Volume: 34
    05/20/2016 Authors: Zeichner SB; Kohn C; Chen Q; Goldstein DA; Montero AJ; Flowers C
  • Deferred treatment as a viable option for selected patients with mantle cell lymphoma.
    Volume: 34
    05/20/2016 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV; Flowers C
  • Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.
    Volume: 34
    05/20/2016 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon M
  • Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
    Med Oncol Volume: 33 Page(s): 48
    05/01/2016 Authors: Goldstein DA; Krishna K; Flowers CR; El-Rayes BF; Bekaii-Saab T; Noonan AM
  • GIFT4 fusokine converts leukemic B cells into immune helper cells.
    J Transl Med Volume: 14 Page(s): 106
    04/27/2016 Authors: Deng J; Pennati A; Cohen JB; Wu Y; Ng S; Wu JH; Flowers CR; Galipeau J
  • Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.
    Hum Mol Genet Volume: 25 Page(s): 1663 - 1676
    04/15/2016 Authors: Machiela MJ; Lan Q; Slager SL; Vermeulen RCH; Teras LR; Camp NJ; Cerhan JR; Spinelli JJ; Wang SS; Nieters A
  • Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma.
    Cancer Epidemiol Volume: 41 Page(s): 139 - 151
    04/01/2016 Authors: Switchenko JM; Bulka C; Ward K; Koff JL; Bayakly AR; Ryan PB; Waller LA; Flowers CR
  • Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy
    Volume: 173 Page(s): 93 - 93
    04/01/2016 Authors: Gopal A; Kahl B; Flowers C; Martin P; Link B; Ansell S; Ye W; Koh B; Abella S; Barr P
  • Idelalisib monotherapy results in durable responses in patients with relapsed or refractory Waldenstrom's macroglobulinemia (WM)
    Volume: 173 Page(s): 102 - 102
    04/01/2016 Authors: Coutre S; Leonard J; Flowers C; Davies A; Jurczak W; Byrd J; Spurgeon S; Peterman S; Holes L; Cho Y
  • Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study
    Volume: 173 Page(s): 100 - 100
    04/01/2016 Authors: Zinzani PL; Salles G; Schuster S; de Vos S; Wagner-Johnston N; Viardot A; Flowers C; Will M; Breuleux M; Godfrey W
  • Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
    Discov Med Volume: 21 Page(s): 181 - 188
    03/01/2016 Authors: Glass S; Phan A; Williams JN; Flowers CR; Koff JL
  • Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
    Clin Colorectal Cancer Volume: 15 Page(s): 1 - 6
    03/01/2016 Authors: Goldstein DA; Zeichner SB; Bartnik CM; Neustadter E; Flowers CR
  • Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Br J Haematol Volume: 172 Page(s): 724 - 734
    03/01/2016 Authors: Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K
  • Perspectives in Oncology Drug Pricing-Reply.
    JAMA Oncol Volume: 2 Page(s): 402 - 403
    03/01/2016 Authors: Goldstein DA; Howard DH; Flowers CR
  • Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study.
    Cancer Epidemiol Biomarkers Prev Volume: 25 Page(s): 264 - 273
    02/01/2016 Authors: Keegan THM; DeRouen MC; Parsons HM; Clarke CA; Goldberg D; Flowers CR; Glaser SL
  • A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Volume: 54 Page(s): 11 - 17
    02/01/2016 Authors: Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F
  • Identifying risk factors for B-cell lymphoma.
    Blood Volume: 127 Page(s): 10 - 11
    01/07/2016 Authors: Flowers CR; Skibola CF
  • Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital.
    J Stem Cell Res Ther Volume: 6
    01/01/2016 Authors: Yun HD; Dossul T; Bernal-Mizrachi L; Switchenko J; Ndibe C; Ibraheem A; Dixon MD; Langston AA; Nooka AK; Flowers CR
  • Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.
    Leuk Lymphoma Volume: 57 Page(s): 842 - 851
    01/01/2016 Authors: Chen Q; Ayer T; Nastoupil LJ; Koff JL; Staton AD; Chhatwal J; Flowers CR
  • Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
    Volume: 126
    12/03/2015 Authors: Lunning MA; Vose J; Fowler N; Nastoupil L; Burger JA; Wierda W; Schreeder MT; Siddiqi T; Flowers C; Cohen JB
  • A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    Volume: 126
    12/03/2015 Authors: de Vos S; Swinnen L; Kozloff M; Wang D; Reid E; Nastoupil L; Fowler N; Cordero J; D'Amico D; Diehl S
  • A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Volume: 126
    12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA
  • Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant
    Volume: 126
    12/03/2015 Authors: Lee MJ; Switchenko J; Thomas JS; Koff JL; Nastoupil L; Lechowicz MJ; Langston AA; Flowers C; Cohen JB
  • Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma
    Volume: 126
    12/03/2015 Authors: Chandra P; Akinbobuyi O; Liao A; Arora J; Chen Z; Lechowicz MJ; Langston AA; Kowalsky J; Cohen JB; Flowers CR
  • Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL (R) Registry
    Volume: 126
    12/03/2015 Authors: Farber CM; Mato A; Nabhan C; Kipps TJ; Flowers C; Kay NE; Lamanna N; Grinblatt DL; Kozloff M; Weiss M
  • Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL (R) Registry
    Volume: 126
    12/03/2015 Authors: Mato A; Nabhan C; Flowers C; Kay NE; Kipps TJ; Grinblatt DL; Lamanna N; Kozloff M; Sullivan K; Flick ED
  • Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy
    Volume: 126
    12/03/2015 Authors: Gopal AK; Kahl BS; Flowers C; Martin P; Link BK; Ansell S; Ye W; Koh B; Abella S; Barr PM
  • Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL (R) Cohort Study
    Volume: 126
    12/03/2015 Authors: Flowers C; Nabhan C; Kay NE; Mato A; Lamanna N; Grinblatt DL; Kipps TJ; Kozloff M; Sullivan K; Flick ED
  • Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Volume: 1 Page(s): 1293 - 1300
    12/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
  • ACR Appropriateness Criteria Diffuse Large B-Cell Lymphoma.
    Am J Clin Oncol Volume: 38 Page(s): 610 - 620
    12/01/2015 Authors: Dabaja BS; Advani R; Hodgson DC; Dhakal S; Flowers CR; Ha CS; Hoppe BS; Mendenhall NP; Metzger ML; Plastaras JP
  • Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
    J Clin Oncol Volume: 33 Page(s): 3842 - 3843
    11/10/2015 Authors: Goldstein DA; El-Rayes BF; Chen Q; Flowers CR
  • Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
    Volume: 33 Page(s): 3727 - 3732
    11/10/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
  • Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study.
    Volume: 26 Page(s): 2311 - 2317
    11/01/2015 Authors: Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD
  • A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Volume: 171 Page(s): 539 - 546
    11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
  • A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 694 - 698
    11/01/2015 Authors: Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK
  • Cutaneous CD30+Mycosis Fungoides: Response to Rotational Total Skin Electron Irradiation
    Volume: 93 Page(s): E452 - E452
    11/01/2015 Authors: Heumann TR; Danish H; Switchenko J; Esiashvili N; Lechwoicz MJ; Flowers CR; Khan MK
  • The Role of Consolidative Radiation Therapy for Patients Over Age 60 With Diffuse Large B Cell Lymphoma (DLBCL)
    Volume: 93 Page(s): S82 - S82
    11/01/2015 Authors: Cassidy RJ; Switchenko J; Jegadeesh N; Rajpara RS; Esiashvili N; Flowers CR; Khan MK
  • Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.
    JAMA Volume: 314 Page(s): 1599 - 1614
    10/20/2015 Authors: Oeffinger KC; Fontham ETH; Etzioni R; Herzig A; Michaelson JS; Shih Y-CT; Walter LC; Church TR; Flowers CR; LaMonte SJ
  • Reply to Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma.
    Cancer Volume: 121 Page(s): 3748
    10/15/2015 Authors: Williams JN; Koff JL; Flowers CR
  • Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.
    BMJ Open Volume: 5 Page(s): e008350
    10/06/2015 Authors: Hung OY; Brown JR; Dai T; Easley KA; Flowers CR; Parashar S
  • Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Transfusion Volume: 55 Page(s): 2351 - 2357
    10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C
  • IDELALISIB EFFICACY AND SAFETY IN FOLLICULAR LYMPHOMA PATIENTS FROM A PHASE 2 STUDY
    Volume: 100 Page(s): 17 - 18
    10/01/2015 Authors: Zinzani PL; Ghia P; Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Flowers CR; Will M; Breuleux M
  • IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM MACROGLOBULINEMIA
    Volume: 100 Page(s): 38 - 39
    10/01/2015 Authors: Zinzani PL; Ghia P; Coutre S; Leonard J; Flowers C; Davies A; Jurczak W; Byrd JC; Spurgeon S; Peterman S
  • Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma.
    Cancer Volume: 121 Page(s): 3387 - 3389
    10/01/2015 Authors: Flowers CR; Nastoupil LJ
  • To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes.
    Curr Hematol Malig Rep Volume: 10 Page(s): 244 - 255
    09/01/2015 Authors: Koff JL; Chihara D; Phan A; Nastoupil LJ; Williams JN; Flowers CR
  • GIFT4-reprogrammed leukemic B cells for CLL immunotherapy.
    Volume: 21
    09/01/2015 Authors: Deng J; Cohen J; Pennati A; Wu Y; Yuan S; Flowers C; Galipeau J
  • Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
    09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
  • Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma.
    Cancer Volume: 121 Page(s): 2858 - 2859
    08/15/2015 Authors: Williams JN; Rai A; Flowers CR
  • Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).
    Blood Volume: 126 Page(s): 851 - 857
    08/13/2015 Authors: Wagner-Johnston ND; Link BK; Byrtek M; Dawson KL; Hainsworth J; Flowers CR; Friedberg JW; Bartlett NL
  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
    J Clin Oncol Volume: 33 Page(s): 2516 - 2522
    08/10/2015 Authors: Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK
  • Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    J Clin Oncol Volume: 33 Page(s): 2399 - 2404
    07/20/2015 Authors: Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM
  • A Plethora of Novel Therapies--Which One to Choose?
    Oncology (Williston Park) Volume: 29 Page(s): 499 - 500
    07/01/2015 Authors: Cohen JB; Flowers CR
  • Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.
    Br J Haematol Volume: 170 Page(s): 85 - 95
    07/01/2015 Authors: Nabhan C; Byrtek M; Rai A; Dawson K; Zhou X; Link BK; Friedberg JW; Zelenetz AD; Maurer MJ; Cerhan JR
  • Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
    Cancer Volume: 121 Page(s): 1800 - 1808
    06/01/2015 Authors: Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
  • A DOSE-ESCALATION STUDY OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199/GDC-0199) PLUS BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN'S LYMPHOMA (NHL)
    Volume: 100 Page(s): 4 - 5
    06/01/2015 Authors: de Vos S; Flowers C; Wang D; Swinnen L; Fowler N; Reid E; Cordero J; Gifford M; D'Amico D; Dunbar M
  • IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)
    Volume: 100 Page(s): 273 - 273
    06/01/2015 Authors: Coutre S; Leonard J; Flowers C; Davies A; Jurczak W; Byrd J; Spurgeon S; Peterman S; Holes L; Cho Y
  • PROSPECTIVELY DEFINED TRIAL-(N=13) AND PATIENT-(N=3837) LEVEL ANALYSIS OF COMPLETE RESPONSE RATES AS SURROGATE END-POINTS FOR PROGRESSION-FREE SURVIVAL (PFS) IN FIRST-LINE FOLLICULAR LYMPHOMA (FL)
    Volume: 100 Page(s): 270 - 270
    06/01/2015 Authors: Sargent D; Shi QS; De Bedout S; Flowers C; Fowler N; Fu T; Hagenbeek A; Herold M; Hoster E; Huang J
  • PROGNOSTIC TESTING PATTERNS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN US PRACTICES FROM THE CONNECT (R) CLL REGISTRY
    Volume: 100 Page(s): 679 - 680
    06/01/2015 Authors: Mato A; Flowers CR; Farber CM; Weiss MA; Kipps TJ; Kozloff MF; Nabhan C; Flinn IW; Grinblatt DL; Lamanna N
  • UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL
    Volume: 100 Page(s): 110 - 111
    06/01/2015 Authors: Lunning MA; Vose JM; Fowler NH; Nastoupil L; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB
  • IDELALISIB EFFICACY AND SAFETY IN FOLLICULAR LYMPHOMA PATIENTS FROM A PHASE 2 STUDY
    Volume: 100 Page(s): 272 - 272
    06/01/2015 Authors: Zinzani P; Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Flowers CR; Will M; Breuleux M; Godfrey WR
  • Impact of racial residential segregation (RRS) on stage at diagnosis and survival after diffuse large B-cell lymphoma (DLBCL).
    Volume: 33
    05/20/2015 Authors: Nastoupil LJ; Flowers C; Lichtensztajn D; Gomez SL; Williams J; Clarke CA; Keegan THM
  • Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.
    Volume: 33
    05/20/2015 Authors: Fowler NH; Nastoupil LJ; Lunning MA; Vose J; Siddiqi T; Flowers C; Cohen JB; Schreeder MT; Miguel M; Blumel S
  • Prognostic testing patterns in CLL pts treated in US practices from the Connect CLL registry
    Volume: 33
    05/20/2015 Authors: Mato A; Flowers C; Farber CM; Weiss MA; Kipps TJ; Kozloff M; Nabhan C; Flinn I; Grinblatt DL; Lamanna N
  • Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
    Volume: 33
    05/20/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers C
  • Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL
    Volume: 33
    05/20/2015 Authors: Lunning MA; Vose J; Fowler NH; Nastoupil LJ; Schreeder MT; Siddiqi T; Flowers C; Cohen JB; Blumel S; Miguel M
  • Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM)
    Volume: 33
    05/20/2015 Authors: Coutre S; Leonard J; Flowers C; Davies AJ; Jurczak W; Byrd JC; Spurgeon SEF; Peterman S; Holes L; Cho Y
  • Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study
    Volume: 33
    05/20/2015 Authors: Salles GA; Schuster SJ; De Vos S; Wagner-Johnston ND; Viardot A; Flowers C; Will M; Breuleux M; Godfrey WR; Sorensen B
  • A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
    Volume: 33
    05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA
  • Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    Volume: 33
    05/20/2015 Authors: De Vos S; Flowers C; Wang D; Swinnen LJ; Fowler NH; Reid EG; Cordero J; Gifford M; D'Amico D; Dunbar M
  • New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy.
    Expert Rev Anticancer Ther Volume: 15 Page(s): 531 - 544
    05/01/2015 Authors: Chihara D; Nastoupil LJ; Williams JN; Lee P; Koff JL; Flowers CR
  • Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
    Leuk Lymphoma Volume: 56 Page(s): 1295 - 1302
    05/01/2015 Authors: Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL
  • Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Int J Radiat Oncol Biol Phys Volume: 92 Page(s): 107 - 112
    05/01/2015 Authors: Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
  • Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique.
    Int J Radiat Oncol Biol Phys Volume: 92 Page(s): 183 - 191
    05/01/2015 Authors: Heumann TR; Esiashvili N; Parker S; Switchenko JM; Dhabbaan A; Goodman M; Lechowicz MJ; Flowers CR; Khan MK
  • Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 270 - 277
    05/01/2015 Authors: Davis CC; Cohen JB; Shah KS; Hutcherson DA; Surati MJ; Valla K; Panjic EH; Handler CE; Switchenko JM; Flowers CR
  • Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-hodgkin lymphoma (iNHL)
    Volume: 169 Page(s): 54 - 54
    04/01/2015 Authors: Davies A; Salles G; Wagner-Johnston N; Kahl B; De Vos S; Schuster S; Jurczak W; Flinn I; Flowers C; Martin P
  • First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    J Clin Oncol Volume: 33 Page(s): 1112 - 1118
    04/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
  • Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci.
    Am J Epidemiol Volume: 181 Page(s): 406 - 421
    03/15/2015 Authors: Wang SS; Vajdic CM; Linet MS; Slager SL; Voutsinas J; Nieters A; de Sanjose S; Cozen W; Alarcn GS; Martinez-Maza O
  • Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era.
    Leuk Lymphoma Volume: 56 Page(s): 557 - 558
    03/01/2015 Authors: Flowers CR; Cohen JB; Khan MK
  • Costs and effectiveness of genomic testing in the management of colorectal cancer.
    Oncology (Williston Park) Volume: 29 Page(s): 175 - 183
    03/01/2015 Authors: Goldstein DA; Shaib WL; Flowers CR
  • Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
    Value Health Volume: 18 Page(s): 189 - 197
    03/01/2015 Authors: Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
    J Clin Oncol Volume: 33 Page(s): 654 - 656
    02/20/2015 Authors: Lyman GH; Bohlke K; Khorana AA; Kuderer NM; Lee AY; Arcelus JI; Balaban EP; Clarke JM; Flowers CR; Francis CW
  • Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
    Leuk Lymphoma Volume: 56 Page(s): 383 - 389
    02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L
  • Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).
    Volume: 33
    01/20/2015 Authors: Goldstein DA; Krishna K; Flowers C; El-Rayes BF; Bekaii-Saab TS; Noonan AM
  • Next-generation prognostic assessment for diffuse large B-cell lymphoma.
    Future Oncol Volume: 11 Page(s): 2443 - 2457
    01/01/2015 Authors: Staton AD; Koff JL; Chen Q; Ayer T; Flowers CR
  • Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era.
    Acta Haematol Volume: 134 Page(s): 109 - 110
    01/01/2015 Authors: Khan MK; Esiashvili N; Flowers C
  • Next-generation surveillance strategies for patients with lymphoma.
    Future Oncol Volume: 11 Page(s): 1977 - 1991
    01/01/2015 Authors: Cohen JB; Kurtz DM; Staton AD; Flowers CR
  • Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect CLL Registry
    Volume: 124
    12/06/2014 Authors: Sharman JP; Mato A; Kay NE; Kipps TJ; Lamanna N; Weiss M; Nabhan C; Flinn I; Grinblatt DL; Kozloff MF
  • Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
    Volume: 124
    12/06/2014 Authors: Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak W; Flinn IW; Flowers CR; Martin P; Viardot A
  • Determinants and Outcomes of the Use of Positron Emission Tomography (PET)-Staging in Newly Diagnosed Follicular Lymphoma (FL)
    Volume: 124
    12/06/2014 Authors: Rai A; Nastoupil LJ; Williams JN; Lipscomb J; Ward K; Howard DH; Flowers CR
  • Rituximab Administration before Allogeneic HSCT Is Associated with Accelerated T Cell Reconstitution after Transplantation: Kinetic Evidence for a Graft-Versus-Leukemia Effect
    Volume: 124
    12/06/2014 Authors: Hosoba S; Flowers CR; Wu CJ; Wrammert JR; Waller EK
  • The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    Volume: 124
    12/06/2014 Authors: de Vos S; Flowers CR; Wang D; Swinnen LJ; Fowler N; Reid E; Gifford M; D'Amico D; Dunbar M; Zhu M
  • Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry
    Volume: 124
    12/06/2014 Authors: Nabhan C; Galanina N; Kay NE; Mato AR; Grinblatt DL; Kipps TJ; Lamanna N; Weiss M; Flinn I; Swern AS
  • Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma
    Volume: 124
    12/06/2014 Authors: Greenough A; Moffitt A; Jima D; Healy J; Patel A; Richards KL; Fedoriw YD; Dunphy C; Choi WWL; Srivastava G
  • Insurance Status Impacts Survival in Follicular Lymphoma
    BLOOD Volume: 124
    12/06/2014 Authors: Nastoupil LJ; Han X; Jemal A; Ward E; Flowers CR
  • Optimal disease surveillance strategies in non-Hodgkin lymphoma.
    Hematology Am Soc Hematol Educ Program Volume: 2014 Page(s): 481 - 487
    12/05/2014 Authors: Cohen JB; Flowers CR
  • Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Clin Colorectal Cancer Volume: 13 Page(s): 219 - 225
    12/01/2014 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
  • Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
    Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e213 - e215
    12/01/2014 Authors: Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA
  • Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.
    Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 460 - 467.e2
    12/01/2014 Authors: Read JA; Koff JL; Nastoupil LJ; Williams JN; Cohen JB; Flowers CR
  • ACR appropriateness criteria follow-up of Hodgkin lymphoma.
    J Am Coll Radiol Volume: 11 Page(s): 1026 - 1033.e3
    11/01/2014 Authors: Ha CS; Hodgson DC; Advani R; Dabaja BS; Dhakal S; Flowers CR; Hoppe BS; Mendenhall NP; Metzger ML; Plastaras JP
  • Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.
    Nat Genet Volume: 46 Page(s): 1233 - 1238
    11/01/2014 Authors: Cerhan JR; Berndt SI; Vijai J; Ghesquires H; McKay J; Wang SS; Wang Z; Yeager M; Conde L; de Bakker PIW
  • Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Ann Oncol Volume: 25 Page(s): 2211 - 2217
    11/01/2014 Authors: Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R
  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
    Blood Volume: 124 Page(s): 2354 - 2361
    10/09/2014 Authors: Petrich AM; Gandhi M; Jovanovic B; Castillo JJ; Rajguru S; Yang DT; Shah KA; Whyman JD; Lansigan F; Hernandez-Ilizaliturri FJ
  • Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)
    ONCOLOGY RESEARCH AND TREATMENT Volume: 37 Page(s): 185 - 185
    10/01/2014 Authors: Dreyling MH; Viardot A; Salles G; Wagner-Johnston ND; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn IW; Flowers C
  • Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma
    CANCER RESEARCH Volume: 74
    10/01/2014 Authors: Cerhan JR; Berndt SI; Vijai J; Ghesquieres H; McKay J; Wang SS; Wang Z; Yeager M; Nieters A; Cox D
  • Puffing the 'Activate' in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF-kappa B Pathway
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S143 - S143
    09/01/2014 Authors: Koff JL; Guo X; Ramachandiran S; Switchenko JM; Mosunjac MB; Neill SG; Mann K; Bagirov M; Flowers CR; Lossos IS
  • Predictors of Local Recurrence in Patients With Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab-Based Chemotherapy Alone: Guiding Decisions for Consolidative Radiation Therapy
    Volume: 90 Page(s): S67 - S67
    09/01/2014 Authors: Jegadeesh N; Esiashvili N; Shi Z; Flowers C; Liu Y; Khan M
  • The Role of Consolidative Radiation Therapy in Early-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP-Based Immunochemotherapy
    Volume: 90 Page(s): S66 - S66
    09/01/2014 Authors: Rajpara RS; Shi Z; Esiashvili N; Flowers CR; Khan MK
  • Total Skin Electron Irradiation (TSEI) Using Rotational Technique for Cutaneous T-Cell Lymphoma
    Volume: 90 Page(s): S680 - S681
    09/01/2014 Authors: Heumann TR; Esiashvili N; Parker S; Switchenko JM; Lechowicz M; Flowers C; Khan MK
  • Routine use of maintenance therapy in follicular lymphoma: examine the rationale for maintenance use before uniformly adopting a strategy.
    Oncology (Williston Park) Volume: 28 Page(s): 787 - 793
    09/01/2014 Authors: Flowers CR
  • Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    J Natl Cancer Inst Monogr Volume: 2014 Page(s): 15 - 25
    08/01/2014 Authors: Cerhan JR; Kricker A; Paltiel O; Flowers CR; Wang SS; Monnereau A; Blair A; Dal Maso L; Kane EV; Nieters A
  • Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    J Natl Cancer Inst Monogr Volume: 2014 Page(s): 26 - 40
    08/01/2014 Authors: Linet MS; Vajdic CM; Morton LM; de Roos AJ; Skibola CF; Boffetta P; Cerhan JR; Flowers CR; de Sanjos S; Monnereau A
  • Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    J Natl Cancer Inst Monogr Volume: 2014 Page(s): 66 - 75
    08/01/2014 Authors: Wang SS; Flowers CR; Kadin ME; Chang ET; Hughes AM; Ansell SM; Feldman AL; Lightfoot T; Boffetta P; Melbye M
  • Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    J Natl Cancer Inst Monogr Volume: 2014 Page(s): 76 - 86
    08/01/2014 Authors: Smedby KE; Sampson JN; Turner JJ; Slager SL; Maynadi M; Roman E; Habermann TM; Flowers CR; Berndt SI; Bracci PM
  • Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    J Natl Cancer Inst Monogr Volume: 2014 Page(s): 130 - 144
    08/01/2014 Authors: Morton LM; Slager SL; Cerhan JR; Wang SS; Vajdic CM; Skibola CF; Bracci PM; de Sanjos S; Smedby KE; Chiu BCH
  • Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
    South Med J Volume: 107 Page(s): 497 - 500
    08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
  • ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.
    Pediatr Blood Cancer Volume: 61 Page(s): 1305 - 1312
    07/01/2014 Authors: Terezakis SA; Metzger ML; Hodgson DC; Schwartz CL; Advani R; Flowers CR; Hoppe BS; Ng A; Roberts KB; Shapiro R
  • The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
    Cancer Volume: 120 Page(s): 1830 - 1837
    06/15/2014 Authors: Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
  • Socioeconomic disparities in lymphoma.
    Blood Volume: 123 Page(s): 3530 - 3531
    06/05/2014 Authors: Flowers CR; Nastoupil LJ
  • PATIENT-REPORTED OUTCOMES DATA FROM A PHASE 2 STUDY OF IDELALISIB IN PATIENTS WITH REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (INHL)
    Volume: 99 Page(s): 143 - 143
    06/01/2014 Authors: Salles G; Wagner-Johnston ND; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn IW; Flowers C; Martin P; Viardot A
  • Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
    06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S
  • Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 US patients (pts).
    Volume: 32
    05/20/2014 Authors: Nabhan C; Byrtek M; Dawson KL; Zhou X; Ziemiecki R; Zelenetz AD; Friedberg JW; Cerhan JR; Flowers C
  • Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC)
    Volume: 32
    05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; Harvey D; El-Rayes BF; Flowers C
  • Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non Hodgkin lymphoma (iNHL)
    Volume: 32
    05/20/2014 Authors: Wagner-Johnston ND; Gopal AK; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn I; Flowers C; Martin P; Viardot A
  • Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy to a large US multicenter cohort.
    Volume: 32
    05/20/2014 Authors: Abramson JS; Feldman T; Kroll A; Muffly LS; Winer ES; Flowers C; Lansigan F; Nabhan C; Nath R; Castillo JJ
  • Characteristics, treatments, and survival outcome of mantle cell lymphoma in women: A single center analysis.
    Volume: 32
    05/20/2014 Authors: Shams SR; Nastoupil LJ; Flowers C
  • Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)
    Volume: 165 Page(s): 2 - 2
    05/01/2014 Authors: Davies A; Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Dansey R
  • Insurance status is related to diffuse large B-cell lymphoma survival.
    Cancer Volume: 120 Page(s): 1220 - 1227
    04/15/2014 Authors: Han X; Jemal A; Flowers CR; Sineshaw H; Nastoupil LJ; Ward E
  • PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma.
    N Engl J Med Volume: 370 Page(s): 1008 - 1018
    03/13/2014 Authors: Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A
  • Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
    Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
    02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ
  • Simplified Technique for Administration of High Dose Melphalan
    Volume: 20 Page(s): S291 - S292
    02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A
  • Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Cancer Volume: 119 Page(s): 4129 - 4136
    12/01/2013 Authors: Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
  • Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
    12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
  • Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
    Cancer Volume: 119 Page(s): 4119 - 4128
    12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S
  • Relationship Between Residential Proximity To Environmental Protection Agency (EPA) Designated Toxic Release Sites and The Risk Of Diffuse Large B-Cell Lymphoma (DLBCL)
    Volume: 122
    11/15/2013 Authors: Bulka C; Nastoupil LJ; Koff J; Bernal L; Ward K; Bayakly R; Switchenko J; Waller L; Flowers CR
  • Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma
    Volume: 122
    11/15/2013 Authors: Chen Q; Ayer T; Rose AC; Nastoupil LJ; Flowers CR
  • Spatial Epidemiology Of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma In The State Of Georgia
    Volume: 122
    11/15/2013 Authors: Bulka C; Nastoupil LJ; Switchenko J; Ward K; Bayakly R; Waller L; Flowers CR
  • Disease Characteristics, Patterns Of Care, and Outcomes Of Follicular Lymphoma (FL) In The Oldest Old
    Volume: 122
    11/15/2013 Authors: Nastoupil LJ; Rai A; Lipscomb J; Nabhan C; Williams JN; Ward K; Howard DH; Flowers CR
  • Patterns Of First-Line Management Strategies In Older Adults With Follicular Lymphoma (FL)
    Volume: 122
    11/15/2013 Authors: Rai A; Nastoupil LJ; Williams JN; Lipscomb J; Ward K; Howard DH; Flowers CR
  • Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
    Volume: 122
    11/15/2013 Authors: Gopal A; Kahl BS; De Vos S; Wagner-Johnston ND; Schuster SJ; Blum KA; Jurczak WJ; Flinn IW; Flowers CR; Martin P
  • Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America
    Volume: 122
    11/15/2013 Authors: Flowers CR; Lill M; Costa LJ; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW
  • Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study
    Volume: 122
    11/15/2013 Authors: Casulo C; Byrtek M; Dawson KL; Zhou X; Farber C; Flowers CR; Hainsworth JD; Link BK; Zelenetz AD; Friedberg JW
  • A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients
    BLOOD Volume: 122
    11/15/2013 Authors: Nabhan C; Byrtek M; Dawson KL; Zhou X; Link BK; Friedberg JW; Zelenetz AD; Cerhan JR; Flowers CR
  • Patterns and Outcomes Of First-Line Management Strategies In Older Adults With Low-Grade Follicular Lymphoma (FL)
    Volume: 122
    11/15/2013 Authors: Rai A; Nastoupil LJ; Lipscomb J; Ward K; Howard DH; Flowers CR
  • Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma
    Volume: 122
    11/15/2013 Authors: Scotland P; Gaulard P; Love CL; Fataccioli V; Travert M; De Leval L; Weisenburger DD; Czader M; Parihar M; Nair R
  • PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study
    Volume: 122 Page(s): 4245 - 4249
    11/15/2013 Authors: Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers C; Link BK; Zelenetz AD; Dawson KL; Reid EG
  • Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
    J Clin Oncol Volume: 31 Page(s): 4132 - 4139
    11/10/2013 Authors: Evens AM; Advani R; Press OW; Lossos IS; Vose JM; Hernandez-Ilizaliturri FJ; Robinson BK; Otis S; Nadav Dagan L; Abdallah R
  • Racial differences in chronic lymphocytic leukemia. Digging deeper.
    Cancer Volume: 119 Page(s): 3593 - 3595
    10/15/2013 Authors: Flowers CR; Pro B
  • Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.
    Support Care Cancer Volume: 21 Page(s): 2853 - 2860
    10/01/2013 Authors: Pashos CL; Flowers CR; Kay NE; Weiss M; Lamanna N; Farber C; Lerner S; Sharman J; Grinblatt D; Flinn IW
  • Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Oncology (Williston Park) Volume: 27 Suppl 2 Page(s): 8 - 12
    10/01/2013 Authors: Nastoupil LJ; Koff JL; Flowers CR
  • Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma.
    Leuk Lymphoma Volume: 54 Page(s): 2122 - 2130
    10/01/2013 Authors: Shi Z; Esiashvili N; Flowers C; Das S; Khan MK
  • Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma.
    Cancer Volume: 119 Page(s): 3309 - 3317
    09/15/2013 Authors: Bulka C; Nastoupil LJ; McClellan W; Ambinder A; Phillips A; Ward K; Bayakly AR; Switchenko JM; Waller L; Flowers CR
  • Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
    09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S
  • The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.
    Expert Rev Anticancer Ther Volume: 13 Page(s): 1089 - 1108
    09/01/2013 Authors: Nastoupil LJ; Sinha R; Flowers CR
  • Peripheral T-cell lymphoma: what's the role for transplant?
    Oncology (Williston Park) Volume: 27 Page(s): 891 - 892
    09/01/2013 Authors: Cohen JB; Flowers CR
  • ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
    Oncology (Williston Park) Volume: 27 Page(s): 786 - 794
    08/01/2013 Authors: Hoppe BS; Hodgson DC; Advani R; Dabaja BS; Flowers CR; Ha CS; Metzger ML; Plastaras JP; Roberts KB; Shapiro R
  • Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Int J Radiat Oncol Biol Phys Volume: 86 Page(s): 569 - 577
    07/01/2013 Authors: Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
  • Communicating safe outpatient management of fever and neutropenia.
    J Oncol Pract Volume: 9 Page(s): 207 - 210
    07/01/2013 Authors: Flowers CR; Karten C
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
    J Clin Oncol Volume: 31 Page(s): 2189 - 2204
    06/10/2013 Authors: Lyman GH; Khorana AA; Kuderer NM; Lee AY; Arcelus JI; Balaban EP; Clarke JM; Flowers CR; Francis CW; Gates LE
  • Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia.
    Volume: 31
    05/20/2013 Authors: Flowers C; Farber CM; Flinn I; Grinblatt DL; Kay NE; Kipps TJ; Kozloff M; Lamanna N; Lerner S; Sharman JP
  • Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
    Volume: 31
    05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK
  • Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.
    Volume: 31
    05/20/2013 Authors: Duc QT; Langston AA; Waller EK; Simon M; Gleason C; Casbourne D; Fisher M; Kaufman JL; Flowers C; Lonial S
  • Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study
    Volume: 31
    05/20/2013 Authors: Said JW; Reeves JA; Flinn I; Tulpule A; Robles RL; Flowers C; DiBella NJ; Kolibaba KS; Venugopal P; Kolevska T
  • Patterns of failure in advanced-stage diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP chemotherapy and the emerging role of consolidative radiotherapy
    Volume: 31
    05/20/2013 Authors: Shi ZJ; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Jiang K; Chen Z; Wang X; Curran WJ; Khan MK
  • Using primary site as a predictor of survival in mantle cell lymphoma.
    Cancer Volume: 119 Page(s): 1570 - 1577
    04/15/2013 Authors: Ambinder AJ; Shenoy PJ; Nastoupil LJ; Flowers CR
  • Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation
    Volume: 48 Page(s): S453 - S453
    04/01/2013 Authors: Johnson HR; Nooka A; Kaufman J; Flowers C; Langston A; Graiser M; Plummer T; Lonial S; Waller E
  • Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.
    Leuk Lymphoma Volume: 54 Page(s): 752 - 759
    04/01/2013 Authors: Imam MH; Shenoy PJ; Flowers CR; Phillips A; Lechowicz MJ
  • Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 460 - 467
    03/01/2013 Authors: Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
  • Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    J Clin Oncol Volume: 31 Page(s): 794 - 810
    02/20/2013 Authors: Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KVI
  • Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
    Volume: 19 Page(s): S191 - S191
    02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M
  • Examining racial differences in diffuse large B-cell lymphoma presentation and survival.
    Leuk Lymphoma Volume: 54 Page(s): 268 - 276
    02/01/2013 Authors: Flowers CR; Shenoy PJ; Borate U; Bumpers K; Douglas-Holland T; King N; Brawley OW; Lipscomb J; Lechowicz MJ; Sinha R
  • Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
    Ann Oncol Volume: 24 Page(s): 441 - 448
    02/01/2013 Authors: Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR
  • Genetic heterogeneity of diffuse large B-cell lymphoma.
    Proc Natl Acad Sci U S A Volume: 110 Page(s): 1398 - 1403
    01/22/2013 Authors: Zhang J; Grubor V; Love CL; Banerjee A; Richards KL; Mieczkowski PA; Dunphy C; Choi W; Au WY; Srivastava G
  • American Cancer Society lung cancer screening guidelines.
    CA Cancer J Clin Volume: 63 Page(s): 107 - 117
    01/01/2013 Authors: Wender R; Fontham ETH; Barrera E; Colditz GA; Church TR; Ettinger DS; Etzioni R; Flowers CR; Gazelle GS; Kelsey DK
  • A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
    Transfusion Volume: 53 Page(s): 76 - 84
    01/01/2013 Authors: Kaufman JL; Flowers CR; Rados KD; Calandra GB; Vose JM; Hewes LB; Lonial S; Langston AA; Khoury HJ; Lechowicz MJ
  • Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin Lymphoma - a commentary on report from Krull and colleagues.
    Transl Pediatr Volume: 2 Page(s): 1 - 2
    01/01/2013 Authors: Esiashvili N; Khan M; Flowers C
  • The genetic landscape of mutations in Burkitt lymphoma.
    Nat Genet Volume: 44 Page(s): 1321 - 1325
    12/01/2012 Authors: Love C; Sun Z; Jima D; Li G; Zhang J; Miles R; Richards KL; Dunphy CH; Choi WWL; Srivastava G
  • A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 393 - 399
    12/01/2012 Authors: Rose AC; Shenoy PJ; Garrett G; Seward M; Kucuk RA; Doksansky H; Nastoupil LJ; Flowers CR
  • Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.
    Community Oncol Volume: 9 Page(s): S85 - S92
    12/01/2012 Authors: Nastoupil LJ; Flowers CR
  • Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS)
    Volume: 120
    11/16/2012 Authors: Nabhan C; Byrtek M; Latta S; Dawson KL; Zhou X; Link BK; Friedberg JW; Cerhan JR; Flowers CR
  • Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study
    Volume: 120
    11/16/2012 Authors: Martin P; Link BK; Byrtek M; Dawson KL; Ziemiecki RM; Friedberg JW; Cerhan JR; Flowers CR
  • GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors
    Volume: 120
    11/16/2012 Authors: Deng J; Pennati A; Li P; Yuan S; Murphy J; Ng S; Sinha R; Flowers CR; Galipeau J
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort
    Volume: 120
    11/16/2012 Authors: Evens AM; Feldman T; Kroll A; Muffly LS; Winer E; Flowers C; Lansigan F; Nabhan C; Nastoupil L; Kim A
  • Considerations in the initial management of follicular lymphoma.
    Community Oncol Volume: 9 Page(s): S53 - S60
    11/01/2012 Authors: Nastoupil L; Sinha R; Hirschey A; Flowers CR
  • Initial management strategies for follicular lymphoma.
    Int J Hematol Oncol Volume: 1 Page(s): 35 - 45
    10/01/2012 Authors: Chen Q; Ayer T; Nastoupil LJ; Seward M; Zhang H; Sinha R; Flowers CR
  • Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.
    Cancer Volume: 118 Page(s): 4842 - 4850
    10/01/2012 Authors: Nabhan C; Byrtek M; Taylor MD; Friedberg JW; Cerhan JR; Hainsworth JD; Miller TP; Hirata J; Link BK; Flowers CR
  • Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
    J Clin Oncol Volume: 30 Page(s): 3368 - 3375
    09/20/2012 Authors: Friedberg JW; Byrtek M; Link BK; Flowers C; Taylor M; Hainsworth J; Cerhan JR; Zelenetz AD; Hirata J; Miller TP
  • Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
    Br J Haematol Volume: 158 Page(s): 608 - 614
    09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L
  • Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.
    Cancer Epidemiol Biomarkers Prev Volume: 21 Page(s): 1520 - 1530
    09/01/2012 Authors: Flowers CR; Fedewa SA; Chen AY; Nastoupil LJ; Lipscomb J; Brawley OW; Ward EM
  • Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
    Biol Blood Marrow Transplant Volume: 18 Page(s): 1287 - 1294
    08/01/2012 Authors: Zhang H; Graiser M; Hutcherson DA; Dada MO; McMillan S; Ali Z; Flowers CR; Waller EK
  • EVALUATION OF THE USE AND EFFICACY OF RITUXIMAB (R) MAINTENANCE REGIMENS IN US PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA (FL): DATA FROM THE NATIONAL LYMPHOCARE STUDY 2004-2007
    Volume: 97 Page(s): 95 - 96
    07/16/2012 Authors: Nastoupil L; Sinha R; Byrtek M; Zhou X; Taylor M; Friedberg J; Link B; Cerhan J; Dawson K; Flowers C
  • EFFECTIVENESS OF FIRST-LINE CHEMOIMMUNOTHERAPY REGIMENS FOR PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA (FL) IN THE US: DATA FROM THE NATIONAL LYMPHOCARE STUDY (NLCS)
    Volume: 97 Page(s): 328 - 328
    07/16/2012 Authors: Nastoupil L; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg J; Link B; Cerhan J; Dawson K; Flowers C
  • A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Cancer Volume: 118 Page(s): 3538 - 3548
    07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT
  • VARIATION IN HEALTH-RELATED QUALITY OF LIFE BY AGE AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    VALUE IN HEALTH Volume: 15 Page(s): A226 - A226
    06/01/2012 Authors: Pashos CL; Flowers CR; Weiss M; Lamanna N; Farber C; Kipps TJ; Lerner S; Kay N; Sharman J; Grinblatt DL
  • Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).
    Volume: 30
    05/20/2012 Authors: Flowers C; Pashos CL; Weiss MA; Lamanna N; Farber CM; Kipps TJ; Lerner S; Kay NE; Sharman JP; Grinblatt DL
  • Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma.
    Eur Oncol Haematol Volume: 8 Page(s): 123 - 126
    05/01/2012 Authors: Nastoupil LJ; Sinha R; Flowers CR
  • Diffuse large B-cell lymphoma: current treatment approaches.
    Oncology (Williston Park) Volume: 26 Page(s): 488 - 495
    05/01/2012 Authors: Nastoupil LJ; Rose AC; Flowers CR
  • Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.
    Blood Lymphat Cancer Volume: 2012 Page(s): 87 - 98
    04/19/2012 Authors: Sinha R; Nastoupil L; Flowers CR
  • Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 53 Page(s): 725 - 727
    04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M
  • Racial Differences in Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
    Volume: 25 Page(s): 328A - 328A
    02/01/2012 Authors: Chastain EC; Fisher KE; Bumpers K; Reddy V; Fu K; Flowers CR; Jaye DL
  • Racial Differences in Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
    Volume: 92 Page(s): 328A - 328A
    02/01/2012 Authors: Chastain EC; Fisher KE; Bumpers K; Reddy V; Fu K; Flowers CR; Jaye DL
  • BI-MODAL AGE DISTRIBUTION OF PATIENTS WITH RELAPSED HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION CORRELATES WITH MARKEDLY INFERIOR SURVIVAL AMONG PATIENTS AGE 35 YEARS AND OLDER
    Volume: 18 Page(s): S296 - S296
    02/01/2012 Authors: Sharma A; Duan M; Chowdhury R; Graiser M; Zhang H; Langston A; Lonial S; Flowers CR; Haight A; Waller EK
  • Exploring risk factors for follicular lymphoma.
    Adv Hematol Volume: 2012 Page(s): 626035
    01/01/2012 Authors: Ambinder AJ; Shenoy PJ; Malik N; Maggioncalda A; Nastoupil LJ; Flowers CR
  • New Challenges in the Management of Diffuse Large B-Cell Lymphoma.
    Treat Strategies Hematol Volume: 2 Page(s): 68 - 73
    01/01/2012 Authors: Flowers CR; Nastoupil LJ; Bernal-Mizrachi L; Rose AC; Sinha R
  • Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
    Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 498 - 506
    12/01/2011 Authors: Shenoy PJ; Malik N; Sinha R; Nooka A; Nastoupil LJ; Smith M; Flowers CR
  • Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
    Volume: 118 Page(s): 855 - 856
    11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A
  • The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
    Volume: 118 Page(s): 1709 - 1710
    11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S
  • Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
    Volume: 118 Page(s): 707 - 708
    11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT
  • Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
    Volume: 118 Page(s): 1287 - 1288
    11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL
  • A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
    BLOOD Volume: 118 Page(s): 1691 - 1691
    11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S
  • A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)
    Volume: 118 Page(s): 49 - 49
    11/18/2011 Authors: Rose AC; Garrett G; Seward M; Shenoy PT; Kucuk RA; Doksansky H; Flowers CR
  • Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia
    Volume: 118 Page(s): 914 - 915
    11/18/2011 Authors: Pashos CL; Flowers CR; Weiss M; Lamanna N; Farber CM; Kipps TJ; Lerner S; Kay N; Sharman JP; Grinblatt DL
  • A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States
    Volume: 118 Page(s): 47 - 47
    11/18/2011 Authors: Nastoupil L; Sinha R; Byrtek M; Taylor M; Cerhan JR; Friedberg J; Link BK; Ziemiecki RM; Hirata JH; Flowers CR
  • Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect (R) CLL Disease Registry
    Volume: 118 Page(s): 1235 - 1236
    11/18/2011 Authors: Sharman J; Flowers CR; Weiss M; Grinblatt D; Farber C; Kay N; Kipps T; Lamanna N; Pashos C; Flinn IW
  • Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma
    Volume: 118 Page(s): 199 - 200
    11/18/2011 Authors: Love CL; Jima D; Zhang J; Grubor V; Miles RR; Dunphy CH; Richards KL; Choi WWL; Au WY; Srivastava G
  • Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004-2007
    Volume: 118 Page(s): 1584 - 1585
    11/18/2011 Authors: Nastoupil L; Sinha R; Byrtek M; Zhou X; Taylor M; Cerhan JR; Friedberg J; Link BK; Hirata JH; Flowers CR
  • Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)
    Volume: 118 Page(s): 351 - 351
    11/18/2011 Authors: Sinha R; Byrtek M; DeJoubner NJ; Nooka AK; Taylor M; Cerhan JR; Friedberg J; Ziemiecki RM; Hirata JH; Link BK
  • Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Transfusion Volume: 51 Page(s): 2175 - 2182
    10/01/2011 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C
  • Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
    Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 379 - 384
    10/01/2011 Authors: Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
  • Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
    Int J Radiat Oncol Biol Phys Volume: 81 Page(s): 175 - 180
    09/01/2011 Authors: Kahn S; Flowers C; Xu Z; Esiashvili N
  • A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Transfusion Volume: 51 Page(s): 1779 - 1783
    08/01/2011 Authors: Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR
  • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    J Clin Oncol Volume: 29 Page(s): 2787 - 2794
    07/10/2011 Authors: Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM
  • SHOULD RADIATION THERAPY (XRT) BE THE STANDARD THERAPEUTIC APPROACH FOR STAGE I FOLLICULAR LYMPHOMA (FL)? A COMPARATIVE EFFECTIVENESS ANALYSIS OF THE NATIONAL LYMPHOCARE STUDY (NLCS)
    Volume: 22 Page(s): 90 - 90
    06/01/2011 Authors: Friedberg J; Byrtek M; Link B; Flowers C; Taylor M; Hainsworth J; Cerhan J; Hirata J; Miller T
  • Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
    Cancer Volume: 117 Page(s): 2530 - 2540
    06/01/2011 Authors: Shenoy PJ; Malik N; Nooka A; Sinha R; Ward KC; Brawley OW; Lipscomb J; Flowers CR
  • Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Link BK; Miller TP; Byrtek M; Cerhan JR; Zelenetz AD; Dillon H; Flowers C; Friedberg JW
  • Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.
    J Clin Oncol Volume: 29 Page(s): 8049
    05/20/2011 Authors: Link BK; Miller TP; Byrtek M; Cerhan JR; Zelenetz AD; Dillon H; Flowers C; Friedberg JW
  • Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices.
    J Clin Oncol Volume: 29 Page(s): 8036
    05/20/2011 Authors: Nooka AK; DeJoubner NJ; Nabhan C; Zhou X; Taylor M; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK
  • Novel agents for diffuse large B-cell lymphoma.
    Expert Opin Investig Drugs Volume: 20 Page(s): 669 - 680
    05/01/2011 Authors: Sinha R; DeJoubner N; Flowers C
  • ACR Appropriateness Criteria on Hodgkin's lymphoma-unfavorable clinical stage I and II.
    J Am Coll Radiol Volume: 8 Page(s): 302 - 308
    05/01/2011 Authors: Das P; Ng A; Constine LS; Advani R; Flowers C; Friedberg J; Hodgson DC; Schwartz CL; Wilder RB; Wilson LD
  • CORRELATION OF PATIENT CHARACTERISTICS INCLUDING AGE, OBESITY, GENDER AND RACE ON THE METABOLISM OF BUSULFAN
    Volume: 17 Page(s): S352 - S353
    02/01/2011 Authors: Hutcherson DA; Mahoney M; Ng A; Wilson NM; Surati M; Shah KS; Flowers CR
  • Clinical, molecular, and environmental risk factors for hodgkin lymphoma.
    Adv Hematol Volume: 2011 Page(s): 736261
    01/01/2011 Authors: Maggioncalda A; Malik N; Shenoy P; Smith M; Sinha R; Flowers CR
  • Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas.
    Expert Opin Biol Ther Volume: 11 Page(s): 31 - 40
    01/01/2011 Authors: Abouyabis AN; Shenoy PJ; Lechowicz MJ; Flowers CR
  • Idiotype vaccine strategies for treatment of follicular lymphoma.
    Future Oncol Volume: 7 Page(s): 111 - 122
    01/01/2011 Authors: Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
  • Incidence patterns and outcomes for hodgkin lymphoma patients in the United States.
    Adv Hematol Volume: 2011 Page(s): 725219
    01/01/2011 Authors: Shenoy P; Maggioncalda A; Malik N; Flowers CR
  • A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
    ISRN Hematol Volume: 2011 Page(s): 623924
    01/01/2011 Authors: Abouyabis AN; Shenoy PJ; Sinha R; Flowers CR; Lechowicz MJ
  • Patterns of social support among lymphoma patients considering stem cell transplantation.
    Soc Work Health Care Volume: 50 Page(s): 815 - 827
    01/01/2011 Authors: Glover R; Shenoy PJ; Kharod GA; Schaefer A; Bumpers K; Berry JTM; Flowers CR
  • Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
    Oncology Volume: 81 Page(s): 12 - 20
    01/01/2011 Authors: Saba NF; Goodman M; Ward K; Flowers C; Ramalingam S; Owonikoko T; Chen A; Grist W; Wadsworth T; Beitler JJ
  • Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
    Blood Volume: 116 Page(s): 5285 - 5288
    12/09/2010 Authors: David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun S-Y; Boise LH; Lonial S
  • Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.
    Blood Volume: 116 Page(s): e118 - e127
    12/02/2010 Authors: Jima DD; Zhang J; Jacobs C; Richards KL; Dunphy CH; Choi WWL; Au WY; Srivastava G; Czader MB; Rizzieri DA
  • A decade of progress in lymphoma: advances and continuing challenges.
    Clin Lymphoma Myeloma Leuk Volume: 10 Page(s): 414 - 423
    12/01/2010 Authors: Flowers CR; Armitage JO
  • Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.
    Volume: 116 Page(s): 650 - 650
    11/19/2010 Authors: Borate U; Shenoy PJ; Donnellan W; Bumpers K; Douglas-Holland T; King N; Lechowicz MJ; The A; Jaye DL; Reddy V
  • Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant.
    Volume: 116 Page(s): 923 - 924
    11/19/2010 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Repfroe H; Kaufman JL; Lonial S; Flowers CR; Lechowicz MJ; Langston A
  • Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).
    Volume: 116 Page(s): 647 - 647
    11/19/2010 Authors: Shenoy PJ; Borate U; Bumpers K; Douglas-Holland T; King N; Lechowicz MJ; Jaye DL; Donnellan W; The A; Reddy V
  • Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS)
    Volume: 116 Page(s): 1690 - 1690
    11/19/2010 Authors: Nabhan C; Byrtek M; Taylor M; Tydell J; Hirata JH; Flowers CR
  • Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)
    Volume: 116 Page(s): 737 - 737
    11/19/2010 Authors: Flowers CR; Taylor M; Byrtek M; Hirata JH; Cerhan J; Hainsworth J; Link B; Miller TP; Dillon H; Friedberg JW
  • Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma
    Volume: 116 Page(s): 351 - 352
    11/19/2010 Authors: Jacobs CL; Patel A; Jima D; Liu Q; Greenough A; Zhang J; Dunphy C; Richards K; Choi W; Srivastava G
  • Pharmocokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Volume: 116 Page(s): 584 - 584
    11/19/2010 Authors: Zhang H; Graiser M; Hutcherson D; Dada MO; McMillan S; Zahir A; Flowers CR; Waller E
  • Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
    Transfusion Volume: 50 Page(s): 2424 - 2431
    11/01/2010 Authors: Akhtari M; Giver CR; Ali Z; Flowers CR; Gleason CL; Hillyer CD; Kaufman J; Khoury HJ; Langston AA; Lechowicz MJ
  • A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
    10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD
  • Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
    Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
    08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
  • Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?
    Clin Lymphoma Myeloma Leuk Volume: 10 Page(s): 270 - 277
    08/01/2010 Authors: Shenoy P; Sinha R; Tumeh JW; Lechowicz MJ; Flowers CR
  • Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL).
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Flowers C; Taylor M; Hirata M; Dillon H; Zelenetz AD; Hainsworth JD; Cerhan JR; Rogers ES; Friedberg JW; Link BK
  • Improving our use and understanding of antibodies in B-cell lymphomas.
    Oncology (Williston Park) Volume: 24 Page(s): 176 - 177
    02/01/2010 Authors: Flowers CR
  • ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma.
    Curr Probl Cancer Volume: 34 Page(s): 211 - 227
    01/01/2010 Authors: Ng A; Constine LS; Advani R; Das P; Flowers C; Friedberg J; Hodgson DC; Schwartz CL; Wilder RB; Wilson LD
  • Improving outcomes for patients with diffuse large B-cell lymphoma.
    CA Cancer J Clin Volume: 60 Page(s): 393 - 408
    01/01/2010 Authors: Flowers CR; Sinha R; Vose JM
  • The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.
    Volume: 114 Page(s): 673 - 673
    11/20/2009 Authors: Deshpande SS; Lechowicz MJ; Sinha R; Kaufman JL; Boise LH; Lonial S; Flowers CR
  • The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated
    BLOOD Volume: 114 Page(s): 1432 - 1432
    11/20/2009 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Lonial S; Flowers CR
  • Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Volume: 114 Page(s): 1151 - 1152
    11/20/2009 Authors: Muringampurath-John D; Flowers CR; Jabbar AA; Sinha R; Arellano M; Bernal-Mizrachi L; Kaufman JL; Jaye DL; Chen Z; Lechowicz MJ
  • A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies
    Volume: 114 Page(s): 948 - 949
    11/20/2009 Authors: Jacobs CL; Jima DD; Zhang J; Dunphy C; Richards KL; Choi WWL; Srivastava G; Evens AM; Gordon LI; Czader M
  • Racial Differences in the Presentation and outcomes of Diffuse Large B-Cell Lymphoma in the United States
    Volume: 114 Page(s): 370 - 370
    11/20/2009 Authors: Malik N; Shenoy PJ; Bumpers K; Sinha R; Flowers CR
  • Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS)
    Volume: 114 Page(s): 562 - 563
    11/20/2009 Authors: Nabhan C; Taylor M; Hirata J; Lin M; Parsons B; Flowers CR
  • Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    J Clin Oncol Volume: 27 Page(s): 5023 - 5030
    10/20/2009 Authors: de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D
  • Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks.
    Epidemiol Infect Volume: 137 Page(s): 1323 - 1332
    09/01/2009 Authors: Galloway RL; Levett PN; Tumeh JW; Flowers CR
  • Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results.
    J Clin Oncol Volume: 27 Page(s): 2
    06/20/2009 Authors: Schuster SJ; Neelapu SS; Gause BL; Muggia FM; Gockerman JP; Sotomayor EM; Winter JN; Flowers CR; Stergiou AM; Kwak LW
  • Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
    Volume: 27
    06/20/2009 Authors: Schuster SJ; Neelapu SS; Gause BL; Muggia FM; Gockerman JP; Sotomayor EM; Winter JN; Flowers CR; Stergiou AM; Kwak LW
  • Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results.
    J Clin Oncol Volume: 27 Page(s): 2
    05/20/2009 Authors: Schuster SJ; Neelapu SS; Gause BL; Muggia FM; Gockerman JP; Sotomayor EM; Winter JN; Flowers CR; Stergiou AM; Kwak LW
  • Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
    J Clin Oncol Volume: 27 Page(s): 8577
    05/20/2009 Authors: Flowers C; Sinha R; Kaufman J; Shenoy P; Lewis C; Bumpers K; Rogatko A
  • Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results
    Volume: 27
    05/20/2009 Authors: Flowers C; Sinha R; Kaufman J; Shenoy P; Lewis C; Bumpers K; Rogatko A
  • Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system.
    Cancer Inform Volume: 8 Page(s): 45 - 64
    04/03/2009 Authors: Huang T; Shenoy PJ; Sinha R; Graiser M; Bumpers KW; Flowers CR
  • Follicular lymphoma in the United States: first report of the national LymphoCare study.
    J Clin Oncol Volume: 27 Page(s): 1202 - 1208
    03/10/2009 Authors: Friedberg JW; Taylor MD; Cerhan JR; Flowers CR; Dillon H; Farber CM; Rogers ES; Hainsworth JD; Wong EK; Vose JM
  • A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Am J Clin Oncol Volume: 32 Page(s): 49 - 55
    02/01/2009 Authors: Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
  • EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION OF TREATMENT
    Volume: 15 Page(s): 128 - 129
    02/01/2009 Authors: Akhtari M; Giver CR; Renfroe HM; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL
  • A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
    CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
    02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT
  • PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
    Volume: 15 Page(s): 154 - 155
    02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ
  • Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    BMC Health Serv Res Volume: 9 Page(s): 9
    01/13/2009 Authors: Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
  • Does the Addition of Involved Field Radiotherapy to High-dose Chemotherapy and Stem Cell Transplantation Improve Outcomes for Patients with Relapsed/Refractory Hodgkin Lymphoma?
    Volume: 75 Page(s): S480 - S480
    01/01/2009 Authors: Kahn ST; Flowers C; Xu Z; Esiashvili N
  • Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy.
    Subst Abuse Volume: 3 Page(s): 41 - 51
    01/01/2009 Authors: Reisman RM; Shenoy PJ; Atherly AJ; Flowers CR
  • Lymphoma and Whole Body CT Scan Mortality Risk
    Volume: 112 Page(s): 477 - 478
    11/16/2008 Authors: Shenoy PJ; Gude T; Sinha R; Flowers CR
  • A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
    Volume: 112 Page(s): 1144 - 1145
    11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK
  • Examining Decision Making Styles in Patients with Sickle Cell Disease (SCD) Regarding Allogeneic Stem Cell Tranplantation (ASCT)
    Volume: 112 Page(s): 69 - 69
    11/16/2008 Authors: Agboola OA; Shenoy PJ; Edwards PJ; Eckman JR; Flowers CR
  • Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
    Volume: 112 Page(s): 1247 - 1247
    11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R
  • Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
    Volume: 112 Page(s): 432 - 432
    11/16/2008 Authors: Giver CR; Akhtari M; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL; Vaughn ML
  • Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States.
    Leuk Lymphoma Volume: 49 Page(s): 2099 - 2107
    11/01/2008 Authors: Abouyabis AN; Shenoy PJ; Lechowicz MJ; Flowers CR
  • Clinical Laboratory Validation of InVivoScribe LymphotrakTM IgH TrackTwoTM Assays for the Detection of Minimal Residual Disease in CLL/SLL
    Volume: 10 Page(s): 584 - 584
    11/01/2008 Authors: Cole JM; Sinha R; Flowers C; Mann K
  • Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
    Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
    10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
  • Idiotype vaccine strategies for improving outcomes in follicular lymphoma.
    Expert Opin Biol Ther Volume: 8 Page(s): 1213 - 1223
    08/01/2008 Authors: Sinha R; Shenoy PJ; Flowers CR
  • The prognostic significance of donor dendritic cells in allogeneic hematopoietic progenitor cell transplant
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Dejoubner N; Ali Z; Grasier M; Hamilton E; Flowers C; Lonial S; Langston A; Waller EK
  • Routine scans for lymphoma produce minimal radiation-related cancer mortality risk
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Shenoy P; Halkar R; Wilson S; Flowers C
  • American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
    J Clin Oncol Volume: 25 Page(s): 5490 - 5505
    12/01/2007 Authors: Lyman GH; Khorana AA; Falanga A; Clarke-Pearson D; Flowers C; Jahanzeb M; Kakkar A; Kuderer NM; Levine MN; Liebman H
  • The effect of rituximab on mobilization with AMD3100 plus G-CSF in patients with relapsed or refractory NHL or HD
    Volume: 110 Page(s): 568A - 568A
    11/16/2007 Authors: Kaufman JL; Cook AM; Flowers C; Langston AA; Lonial S; Lechowicz MJ; Khoury HJ; Calandra G; Waller N
  • Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed/refractory B-cell chronic lymphocytic leukemia (CLL).
    Volume: 110 Page(s): 915A - 915A
    11/16/2007 Authors: Flowers C; Rosenthal H; Brown J; Stock W; Katzen H; Lakhanpal S; Jaye D
  • A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 110 Page(s): 288A - 289A
    11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK
  • Examining decision making styles in patients with lymphoma and multiple myeloma considering autologous stem cell transplantation
    Volume: 110 Page(s): 975A - 976A
    11/16/2007 Authors: Agboola OA; Edwards P; Flowers CR
  • Therapeutic drug monitoring (TDM) of IV busulfan in patients with severe obesity
    Volume: 110 Page(s): 592A - 592A
    11/16/2007 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Sanvidge K; Stricker SR; Langston A; Flowers C; Lechowicz MJ; Waller N; Lonial S
  • Maintenance therapy in lymphoma.
    Clin Lymphoma Myeloma Volume: 7 Page(s): 507 - 513
    09/01/2007 Authors: Mihelic R; Kaufman J; Lonial S; Flowers C
  • Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 895 - 904
    08/01/2007 Authors: Ninan MJ; Flowers CR; Roback JD; Arellano ML; Waller EK
  • Racial variation in colorectal polyp and tumor location.
    J Natl Med Assoc Volume: 99 Page(s): 723 - 728
    07/01/2007 Authors: Thornton JG; Morris AM; Thornton JD; Flowers CR; McCashland TM
  • The occurrence of idiopathic secondary post-transplant thrombocytopenia and the kinetics of platelet recovery predict survival in patients undergoing autologous hematopoietic progenitor cell transplantation
    Volume: 25
    06/20/2007 Authors: Waller E; Ninan MJ; Roback J; Arellano M; Flowers C
  • Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Volume: 25
    06/20/2007 Authors: Flowers CR; Sambrook JC; Briggs A; Osenenko K; Wang H; Dalal MR
  • BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Expert Rev Vaccines Volume: 6 Page(s): 307 - 317
    06/01/2007 Authors: Flowers CR
  • Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 746 - 747
    06/01/2007 Authors: Santos EC; Sessions J; Hutcherson D; Flowers C; Langston A; Waller EK
  • Development of query strategies to identify a histologic lymphoma subtype in a large linked database system.
    Cancer Inform Volume: 3 Page(s): 149 - 158
    05/04/2007 Authors: Graiser M; Moore SG; Victor R; Hilliard A; Hill L; Keehan MS; Flowers CR
  • Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. (vol 47, pg 629, 2007)
    TRANSFUSION Volume: 47 Page(s): 952 - 952
    05/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi SS; Teagarden D; Hamilton ES; Waller EK
  • Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
    Transfusion Volume: 47 Page(s): 629 - 635
    04/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK
  • A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 13 Page(s): 56 - 56
    02/01/2007 Authors: Lonial S; Kaufman J; Langston AA; Khoury HJ; Torre C; Lechowicz MJ; Flowers C; Waller EK
  • Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 116 - 123
    01/01/2007 Authors: Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
  • Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Value Health Volume: 10 Page(s): 23 - 31
    01/01/2007 Authors: Moore S; Tumeh J; Wojtanowski S; Flowers C
  • Race and disparities in health.
    Curr Probl Cancer Volume: 31 Page(s): 114 - 122
    01/01/2007 Authors: Brawley OW; Jani AB
  • Racial differences in the incidence and outcomes for patients with hematological malignancies.
    Curr Probl Cancer Volume: 31 Page(s): 182 - 201
    01/01/2007 Authors: Flowers CR; Glover R; Lonial S; Brawley OW
  • Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results.
    Volume: 108 Page(s): 208A - 208A
    11/16/2006 Authors: De Vos S; Dakhil SR; McLaughlin P; Saleh MN; Belt R; Flowers C; Holladay C; Knapp M; Boral A; Zhang T
  • Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
    Volume: 108 Page(s): 554A - 554A
    11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ
  • Mechanism for the immuno-suppresion activity of pentostatin: Selective apoptosis of naive T cell subsets.
    BLOOD Volume: 108 Page(s): 380B - 380B
    11/16/2006 Authors: Smith MM; Powers W; Giver CR; Waller N; Flowers C
  • Patients receiving patifermin in conjunction with melphalan 200 required fewer platelet transfusions: Analysis of a retrospective cohort study.
    Volume: 108 Page(s): 407B - 407B
    11/16/2006 Authors: Hutcherson DA; Langston A; Lin CH; Flowers C; Lechowicz MJ; Waller N; Sessions JK; Kaufman JL; Jean Khoury H; Lonial S
  • Impact of revised international working group criteria on lymphoma patients undergoing autologous stem cell transplantation.
    Volume: 108 Page(s): 873A - 873A
    11/16/2006 Authors: Lucas AS; Flowers C; Langston A; Lonial S; Lechowicz MJ; Waller N; Kaufman JL; Jean Khoury H
  • Determining the benefits of rituximiab plus chemotherapy for patients with untreated follicular lymphoma: A comprehensive meta-analysis.
    Volume: 108 Page(s): 950A - 950A
    11/16/2006 Authors: Orina JN; Flowers CR
  • Early estimates of safety for alemtuzumab combined with fludarabine for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia: Phase II multicenter study.
    Volume: 108 Page(s): 336B - 336B
    11/16/2006 Authors: Brown JR; Stock W; Katzen HI; Suarez AJ; Lakhanpal S; Leis JF; Flowers C
  • Benefits of CHOP-14 followed by transplantation in patients with peripheral T-cell lymphoma.
    Volume: 108 Page(s): 254B - 254B
    11/16/2006 Authors: Abouyabis AN; Lechowicz M; Mann K; Heffner LT; Winton E; Bucur S; Flowers CR
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus G-CSF) on dendritic cell and T-Cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant.
    Volume: 108 Page(s): 964A - 964A
    11/16/2006 Authors: Lonial S; McMillan S; Torre C; Langston AA; Hamilton E; Cook A; Flowers C; Kaufman JL; Lechowicz MJ; Waller N
  • T cell reconstitution in first 200 days post transplantation predicts long term survival in allogeneic hematopoetic progenitor cell transplantation (HPCT).
    Volume: 108 Page(s): 920A - 920A
    11/16/2006 Authors: Vann L; Larks M; Flowers C; Lonial S; Kaufman J; Lechowicz MJ; Langston AA; Khoury J; Waller N
  • Infliximab for the treatment of chronic graft versus host disease.
    Volume: 108 Page(s): 818A - 818A
    11/16/2006 Authors: Tolbert E; Waller N; Khoury HJ; Lechowicz MJ; Flowers C; Lonial S; Vann L; Langston A; Kaufman JL
  • Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.
    Int J Radiat Oncol Biol Phys Volume: 66 Page(s): 961 - 965
    11/15/2006 Authors: Kahn ST; Flowers C; Lechowicz MJ; Hollenbach K; Johnstone PAS
  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
    10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
  • Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    J Clin Oncol Volume: 24 Page(s): 6060
    06/20/2006 Authors: Moore SG; Tumeh J; Flowers CR
  • Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    Volume: 24 Page(s): 315S - 315S
    06/20/2006 Authors: Moore SG; Tumeh J; Flowers CR
  • A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.
    J Clin Oncol Volume: 24 Page(s): 17550
    06/20/2006 Authors: Kaufman JL; Waller EK; Torre C; McMillan S; Langston A; Flowers C; Lechowicz M; Tighiouart M; Lonial S
  • Receiver operator characteristics of the Sysmex HPC measurement used to initiate apheresis of blood hematopoietic progenitor cells
    Volume: 12 Page(s): 10 - 10
    02/01/2006 Authors: Hamilton ES; Flowers CR; Vaughn ML; Minerley M; Waller EK
  • Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
    Volume: 12 Page(s): 132 - 132
    02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J
  • Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
    Volume: 12 Page(s): 69 - 70
    02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A
  • Decreased incidence of relapse in patients with acute leukemia transplanted from matched unrelated donors: Induction of GvL
    Volume: 106 Page(s): 570A - 571A
    11/16/2005 Authors: Arellano ML; Langston A; Lonial S; Flowers C; Khoury JH; Winton E; Waller EK; Mary LJ
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus GCSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant
    Volume: 106 Page(s): 555A - 555A
    11/16/2005 Authors: Lonial S; Torre C; Langston AA; McMillans S; Hamilton E; Flowers C; Lechowicz MJ; Waller EK
  • Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: A systematic review and meta-analysis.
    Volume: 106 Page(s): 88A - 89A
    11/16/2005 Authors: Orina JN; Moore SG; Lechowicz MJ; Flowers CR
  • Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
    Volume: 106 Page(s): 237B - 237B
    11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E
  • Systematic review and meta-analysis of radioimmunotherapy regimens in patients with relapsed follicular and transformed nonhodgkins lymphomas.
    Volume: 106 Page(s): 870A - 871A
    11/16/2005 Authors: Orina JN; Moore SG; Lechowicz MJ; Flowers CR
  • Ex vivo fludarabine selectively depletes human naive T-Cell subsets: A step toward modifying donor lymphocyte infusion.
    Volume: 106 Page(s): 312A - 312A
    11/16/2005 Authors: Smith MM; Giver CR; Waller EK; Flowers CR
  • Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
    Volume: 106 Page(s): 210B - 210B
    11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E
  • Assessing the cost-effectiveness of adding aprepitant to the ASCO standard for prophylaxis of chemotherapy induced nausea and vomiting.
    Volume: 23 Page(s): 530S - 530S
    06/01/2005 Authors: Moore SG; Tumeh JW; Woftanowski S; Flowers CR
  • Results of a clinical phase I dose-escalation study of cylarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma.
    Volume: 23 Page(s): 607S - 607S
    06/01/2005 Authors: Arellano ML; Lonial S; Langston A; Flowers C; Heffner T; Hutcherson D; Winton E; Waller E
  • Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.
    Expert Rev Pharmacoecon Outcomes Res Volume: 5 Page(s): 153 - 162
    04/01/2005 Authors: Tumeh JW; Moore SG; Shapiro R; Flowers CR
  • Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma
    Volume: 11 Page(s): 6 - 6
    02/01/2005 Authors: Kaufman JL; Lonial S; Hicks M; Langston A; Flowers C; Lechowicz MJ; Khoury H; Waller EK
  • Value of PET restaging after chemotherapy for non-Hodgkins lymphoma: Implications for consolidation radiotherapy
    Volume: 63 Page(s): S422 - S422
    01/01/2005 Authors: Kahn S; Koshy M; Flowers C; Lechowicz M; Hollenbach K; Johnstone PA
  • Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Cancer J Volume: 11 Page(s): 425 - 431
    01/01/2005 Authors: Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PAS
  • A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 104 Page(s): 502A - 502A
    11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ
  • Predictors of more rapid lymphoid reconstitution after allogeneic transplantation
    Volume: 104 Page(s): 864A - 864A
    11/16/2004 Authors: Arellano ML; Moore SG; Kudchadkar R; Flowers CR; Langston AA; Lonial S; Lechowicz MJ; Waller EK
  • A randomized trial to evaluate the impact of cytokines on dendritic cell, T-cell and T-cell function when mobilizing normal donors for allogeneic progenitor cell transplant: An interim analysis.
    Volume: 104 Page(s): 780A - 780A
    11/16/2004 Authors: Lonial S; Torre C; Hicks M; Mcmillan S; Langston AA; Flowers CR; Lechowicz MJ; Waller EK
  • Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.
    Blood Volume: 104 Page(s): 1550 - 1558
    09/01/2004 Authors: Diaconescu R; Flowers CR; Storer B; Sorror ML; Maris MB; Maloney DG; Sandmaier BM; Storb R
  • Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
    Blood Volume: 104 Page(s): 961 - 968
    08/15/2004 Authors: Sorror ML; Maris MB; Storer B; Sandmaier BM; Diaconescu R; Flowers C; Maloney DG; Storb R
  • The role of cost-effectiveness analysis in the era of pharmacogenomics.
    Pharmacoeconomics Volume: 22 Page(s): 481 - 493
    01/01/2004 Authors: Flowers CR; Veenstra D
  • Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors.
    Volume: 102 Page(s): 77A - 78A
    11/16/2003 Authors: Diaconescu R; Flowers C; Storer B; Sorror ML; Maris M; Maloney DG; Chauncey T; Sandmaier BM; Storb RF
  • Transplant-related Toxicities (TRT) and mortality following HLA matched unrelated donor hematopoietic cell transplantation (URD-HCT) using nonmyeloablative (NM) compared to myeloablative (M) conditioning: Influence of pretransplant comorbidities.
    Volume: 102 Page(s): 78A - 78A
    11/16/2003 Authors: Sorror ML; Maris M; Storer B; Sandmaier BM; Diaconescu R; Flowers C; Maloney DG; Storb RF
  • Can pharmacogenomics be cost-effective?: An analysis of genotype-individualized therapy for children with acute lymphoblastic leukemia.
    Volume: 102 Page(s): 496A - 496A
    11/16/2003 Authors: Flowers CR; Veenstra DL
  • Comparing the cost-effectiveness of the triple test score to traditional methods for evaluating palpable breast masses.
    Med Care Volume: 41 Page(s): 962 - 971
    08/01/2003 Authors: Morris AM; Flowers CR; Morris KT; Schmidt WA; Pommier RF; Vetto JT
  • Racial variation in colorectal polyp and tumor location: Implications for screening
    AMERICAN JOURNAL OF GASTROENTEROLOGY Volume: 97 Page(s): S244 - S244
    09/01/2002 Authors: Gore JI; Morris A; Flowers CR; Thornton JD; McCashland TM
  • Allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning for patients with chronic lymphocytic leukemia.
    BLOOD Volume: 98 Page(s): 418A - 418A
    11/16/2001 Authors: Flowers CR; Maloney DG; Sandmaier BM; Shizuru JA; McSweeney PA; Chauncey TR; Niederwieser D; Sahebi F; Agura E; Blume K
  • Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Ann N Y Acad Sci Volume: 938 Page(s): 328 - 337
    06/01/2001 Authors: Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T
  • Regimen related toxicities associated with nonmyeloablative conditioning and postgrafting cyclosporine and mycophenolate mofetil.
    BLOOD Volume: 96 Page(s): 521A - 521A
    11/16/2000 Authors: Flowers CR; Sandmaier BM; Maloney DG; Shizuru JA; Niederwieser D; McSweeney PA; Chauncey TR; Sahebi F; Blume K; Forman S
  • Cyclosporin and the clinical investigator.
    Nat Med Volume: 3 Page(s): 590
    06/01/1997 Authors: Sthelin HF
  • Clinical investigators as critical determinants in pharmaceutical innovation.
    Nat Med Volume: 3 Page(s): 136 - 143
    02/01/1997 Authors: Flowers CR; Melmon KL
  • Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems.
    Proc AMIA Annu Fall Symp Page(s): 223 - 227
    01/01/1997 Authors: Flowers CR; Garber AM; Bergen MR; Lenert LA
  • Neurochemical predictors and correlates of vulnerability to cocaine use.
    NIDA Res Monogr Volume: 159 Page(s): 228 - 263
    01/01/1996 Authors: King RJ; Flowers C
  • IMPACT: an object-oriented graphical environment for construction of multimedia patient interviewing software.
    Proc Annu Symp Comput Appl Med Care Page(s): 319 - 323
    01/01/1995 Authors: Lenert LA; Michelson D; Flowers C; Bergen MR
  • 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 7-8 November 2011. Abstracts.

    Authors: Zhang J; Grubor V; Love CL; Banerjee A; Richards KL; Miezcowski P; Dunphy CH; Choi WWL; Auv W-Y; Srivastava G
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements